

1 Oral Fungal Infection Impacts Epithelial Innate Immunity to Promote Local and Distal Squamous 2 Cell Carcinoma Progression

3
4 Xin Li¹, Amit Kumar Singh¹, Na-Young Song^{1,11}, Jonathan H. Badger², Rodrigo Xavier das Neves²,
5 Chengfei Jiang⁴, Feng Zhu¹, Zhonghe Sun³, Gongping Shi¹, Jami Willette-Brown¹, Debra Tross¹, Peilin
6 Zhang⁵, Elise M.N. Ferré⁶, Amir Seyedmousavi⁷, King Chan⁸, Xia Xu⁸, Sayantan Banerjee¹, Timothy
7 Gower⁹, Thorkell Andresson⁸, Yongmei Zhao¹⁰, Bao Tran¹⁰, Colm O'hUigin², Xiaolin Wu³, Michail S.
8 Lionakis⁶, Giorgio Trinchieri², and Yinling Hu¹

9
10 ¹Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes
11 of Health, Frederick, MD 21702, USA

12 ²Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute,
13 National Institutes of Health, Bethesda, MD 20892, USA

14 ³Genomics Technology Laboratory, Cancer Research Technology Program, Frederick National
15 Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA

16 ⁴Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health,
17 Bethesda, MD 20892, USA

18 ⁵PZM Diagnostics LLC, Charleston, WV 25314, USA

19 ⁶Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute
20 of Allergy and Infectious Diseases, Bethesda, MD 20892, USA

21 ⁷Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of
22 Health, Bethesda, MD 20892, USA

23 ⁸Protein Characterization Laboratory, Cancer Research Technology Program, Frederick National
24 Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA

25 ⁹Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD
26 21702, USA

27 ¹⁰Sequencing Facility, Cancer Research Technology Program, Frederick National Laboratory for Cancer
28 Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA

29 ¹¹Present address: Department of Oral Biology, Yonsei University College of Dentistry, 50-1 Yonsei-ro,
30 Seodaemun-gu, Seoul, 03722, Republic of Korea

31

32 X. Li, A.K. Singh, N. Song, and J.H. Badger contributed equally to this article.

33 **Corresponding author:** Yinling Hu, Laboratory of Cancer Immunometabolism, Center for Cancer
34 Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21701. Email:
35 huy2@mail.nih.gov. Giorgio Trinchieri, Laboratory of Integrative Cancer Immunology, Center for Cancer
36 Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. Email:
37 trinchig@mail.nih.gov

38

39 **Running title:** Oral fungus and tumor interaction impairs innate immunity

40

41 **Key words:** Fungi, neutrophils, epithelial innate immunity, systemic inflammation, tumor-associated
42 macrophages, STAT3, IL-1 β , and EGFR, carcinogenesis

43

44 **Conflict of Interest:** The authors declare no conflict of interest.

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63 ABSTRACT

64 Fungi have been detected within human tumors and shown to support tumor progression. A better
65 understanding of how intratumoral fungi evade innate immunity, remodel the tumor microenvironment
66 (TME), and promote tumorigenesis may provide insights into cancer pathogenesis and therapeutic
67 strategies. Here, we showed that aggressive human head and neck squamous cell carcinomas (HNSCCs)
68 harbor an elevated fungal burden, including the environmental fungus *Cladosporium cladosporioides*,
69 and are infiltrated by *IL1B*-high neutrophils with impaired reactive oxygen species (ROS) production and
70 phagocytosis, as well as *IL1B*-high macrophages. In a mouse model in which *Ikka* ablation drives
71 tumorigenesis through EGFR and STAT3 activation, oral *C. cladosporioides* infection recapitulated key
72 features of the human HNSCC TME, elevated serum IL-1 β and IL-17A levels, and promoted both oral
73 and skin SCC development. Oral fungal infection also increased the acidic metabolites uric acid and
74 lactate in the TME. These metabolites enhanced *C. cladosporioides*-induced IL-1 β production while
75 reducing ROS production in neutrophils, thereby impairing fungal clearance. Mechanistically, *C.*
76 *cladosporioides*, IL-1 β , and IL-17A activated STAT3 and cyclin D1 signaling in SCC cells. Epithelial
77 *Stat3* deletion abrogated both *Ikka* loss-driven and fungus-enhanced oral and skin carcinogenesis,
78 reduced macrophage accumulation, restored normal oral neutrophil phenotypes, and cleared oral fungal
79 infection. Furthermore, IL-1 β induced by *C. cladosporioides* inoculation drove systemic inflammation
80 that promoted skin SCC via an IL-1 β /IL-1R feedback loop involving neutrophils and macrophages.
81 Together, these findings identify a fungus-driven immunosuppressive circuit in which tumor-derived
82 acidic metabolites impair antifungal immunity, thereby promoting both local and distal SCC progression.

83

84

85

SIGNIFICANCE: Fungal infections enhance IL-1 β production and STAT3 signaling to promote infiltration of inflammatory neutrophils and macrophages that support squamous cell carcinoma progression, providing promising targets for cancer treatment and prevention.

109 INTRODUCTION

110 Pathogens and opportunistic microorganisms must overcome innate immune resistance mechanisms
 111 to cause disease. However, how interactions between pathogens and pattern recognition receptors (PRRs)
 112 dictate either the containment of pathogen spreading or disease progression remains unclear (1).
 113 Neutrophils provide the first line of defense against fungal pathogens by deploying fungicidal
 114 mechanisms, including the generation of reactive oxygen species (ROS) and granule protease-mediated
 115 phagocytosis (2-4). Intriguingly, diverse fungal taxa have been detected in human cancers (5-7).

116 To date, most studies have focused on fungus-induced inflammation in tumorigenesis and PRR
 117 activation in macrophages. Chronic *Cladosporium cladosporioides* infection in kinase-dead *Ikka* knockin
 118 mice promotes macrophage infiltration, T cell-mediated autoinflammation with blunted *Il17a* expression,
 119 and esophageal squamous cell carcinoma (ESCC) (8,9). Antifungal treatment prevents the development
 120 of fungus-promoted ESCC, pancreatic ductal adenocarcinoma (PDA), breast cancer, and lung
 121 adenocarcinoma (ADC) (5,10,11). In PDA, *Malassezia* translocates from the gut to the pancreas, binds
 122 mannose-binding lectin, and activates 3a/C3aR signaling (6), while *Alternaria alternata* activates Dectin-
 123 1 on PDA cells (12). Antibiotic-induced fungal expansion impairs radiotherapy in mammary cancer and
 124 melanoma via Dectin-1-mediated immunosuppressive macrophages (10). Similarly, *Aspergillus sydowii*
 125 recruits polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) and promotes Kras^{G12D}-
 126 induced lung ADC via Dectin-1/CARD9 pathway in mice (13), although this PMN-MDSC population is
 127 not well characterized. However, how tumor-associated fungi evade immune surveillance and persist in
 128 the tumor microenvironment (TME) remains to be characterized.

129 Head and neck SCC (HNSCC), including oral SCC, is the sixth most common human cancer
 130 worldwide. The oral cavity provides a unique niche for commensal and environmental microbiota (5,14-
 131 16). HNSCCs arise from stratified or pseudostratified epithelial surfaces that are directly exposed to

environmental microbes, yet they infrequently harbor *RAS* mutations (cBioPortal). *C. cladosporioides* is a common environmental fungus associated with respiratory allergies and intrabronchial lesions in humans. Both *C. cladosporioides* and its metabolite, calphostin-C, which inhibits protein kinase C (PKC) and activates EGFR signaling, have been detected in human HNSCC, ESCC, breast cancer, glioblastoma, and lung cancers (7-9,17-19). Thus, defining how environmental fungi modulate epithelial oncogenic pathways and impair antitumor immunity may provide new insights into HNSCC pathogenesis and therapy.

Previously, we reported that mice with keratinocyte-specific *Ikka* ablation develop EGFR-dependent spontaneous skin SCC associated with increased STAT3 activity (20,21). STAT3 signaling regulates major immunoregulatory and inflammatory pathways (22,23). In this study, we targeted these pathways to engineer a novel oral SCC model that recapitulates key features of human HNSCC. We then used this model to investigate how oral *C. cladosporioides* infection influences local and distal epithelial immunity-associated carcinogenesis, and to evaluate the clinical relevance of these findings for improving the prognosis and treatment of human HNSCC.

146

Materials and Methods

Mouse strains and ethics statement

All mice used in this study were cared for in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of the National Institutes of Health. All animal experiments (Protocols 17-051, 17-052, 20-051, 20-052, 23-051, and 23-052) were approved by IACUC. *Ikka^{ff}*,(21) K15.Cre^{PR1} (stock #005249, The Jackson Laboratory, RRID:IMSR_JAX:005249) and *Stat3^{ff}* (stock #016923, The Jackson Laboratory, RRID:IMSR_JAX:016923) mice were on a C57BL/6 background. *Il1r1^{-/-}* mice (B6.129S7-Il1r1tm1Imx/J) were purchased from the Jackson Laboratory (Stock#003245,

RRID:IMSR_JAX:003245). *Il1b*^{-/-} mice were gifts from Dr. Yoichiro Iwakura, the University of Tokyo and Dr. Katrin Mayer-Barber, National Institutes of Health.

157

158 **Cell culture**

Human A431 epidermoid carcinoma cells (ATCC CRL-1555) and SCC-25 squamous cell carcinoma cells (ATCC CRL-1628) were obtained from the American Type Culture Collection (ATCC). Mouse B16F1 melanoma cells were obtained from the NIH cell repository. A431 and B16F1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). SCC-25 cells were cultured in a 1:1 mixture of DMEM and Ham's F-12 medium supplemented with 10% FBS and 400 ng/mL hydrocortisone. Cells were maintained at 37°C in a humidified atmosphere containing 5% CO₂.

The identities of A431 and SCC-25 cells were verified by short tandem repeat (STR) profiling, and B16F1 cells were authenticated by mouse STR profiling. All cell lines were confirmed to be negative for mycoplasma contamination using a PCR-based mycoplasma detection assay before use in experiments. Early-passage cells were expanded and cryopreserved as multiple aliquots to establish working cell stocks. For all experiments, cells were used within 10 passages after thawing. Cultures exceeding 10 passages were discarded and replaced with freshly thawed cells from the cryopreserved stocks.

172

173 **Gene ablation and mouse experiments**

C57BL/6 *Ikka*^{fl/fl} (wild-type, WT), *Ikka*^{fl/fl};K15.Cre, and *Ikka*^{fl/fl}*Stat3*^{fl/fl};K15.Cre mice were shaved at 6–8 weeks old. Then, 40 µg of RU486 (M8046, Sigma-Aldrich) in 200 µL of acetone was topically applied to the dorsal mouse skin and 200 µL of RU486 (200 µg/mL) in 50% DMSO was applied to the oral cavity for 10 consecutive days to generate *Ikka*^{ΔSOE} and *Ikka*^{ΔSOE}*Stat3*^{ΔSOE} mice. After RU486 treatment, WT,

178 *Ikka*^{ΔSOE}, and *Ikka*^{ΔSOE}*Stat3*^{ΔSOE} mice were inoculated orally with 30 μL of 2×10^7 CFU *Cladosporium*
 179 *cladosporioides* or *Saccharomyces cerevisiae* (9). The inoculation was performed weekly for a total of 25
 180 weeks. For the carcinogenesis experiment, mice were euthanized 13 months after the gene deletion, and
 181 the oral cavity and skin specimens were examined by histology, immunostaining, and various analyses.
 182 For EGFR inhibitor GW2974 (G0668, Sigma-Aldrich) treatment, experimental mice were orally infected
 183 with *C. cladosporioides* once per week for two weeks. Then, 0.3 μg GW2974 in 30 μL of PBS with 50%
 184 DMSO was dropped into the mouth of mice three times per week for four weeks. PBS with 50% DMSO
 185 in 30 μL was used as a control treatment. Oral swabs were collected after treatment with both *C.*
 186 *cladosporioides* and GW2974 for two months for examining fungal growth. For oral swabbing, 500 μL
 187 of sterile distilled water was added to a 1.5 mL tube. A cotton swab was soaked into the water, the extra
 188 water was squeezed off against the tube wall, and the swab was twirled slowly and thoroughly throughout
 189 the oral cavity of the mouse. The cotton swab was rinsed in the water in the 1.5 mL tube several times,
 190 and the extra water was squeezed out. All procedures, including swabbing and rinsing durations, were
 191 ultimately standardized at the same level (9).

192 For the subcutaneous B16F1 murine model, a 3×10^5 B16F1 (DCTD Tumor Repository, Sample ID#
 193 0507501, RRID:CVCL 0158) cell suspension in 200 μL PBS was subcutaneously injected into the right
 194 flank of C57BL/6 mice at 8 weeks of age. Mice were divided into different groups with treatments. Tumor
 195 volume was recorded every day using a vernier caliper (tumor volume = $\frac{1}{2}$ length $\times$ width²). Once tumor
 196 volume reached approximately 40 mm³ at day 8 post injection, mice were randomly allocated to different
 197 experimental groups and were inoculated orally with a fungal load of 2×10^7 CFU/ mouse in 30 μL PBS
 198 every other day. In the meantime, for neutralization of IL-1β, mice were injected intraperitoneally every
 199 other day with *InVivo*MAb anti-mouse/rat IL-1β antibody (200 μg per mouse, BE0246, BioX Cell,
 200 RRID:AB 2687727) or *InVivo*MAb polyclonal Armenian hamster IgG (200 μg per mouse, BE0091, BioX

Cell, RRID:AB 2687680). For macrophage depletion, mice were injected intraperitoneally every other day with 100 μ L m-Clodrosome® liposomal clodronate or m-Encapsome® control liposome from a Mannosylated Macrophage depletion kit (5mg/mL, CLD-8914, Encapsula Nano Science) in 100 μ L PBS. Each experiment was repeated three times. For the bone marrow (BM) transfer experiment, wild-type (WT) recipient mice were maintained on aqueous antibiotics by supplementing the water with amoxycillin for one week before BM transfer. After one week post transfer, 5×10^6 BM cells in 200 μ L PBS through tail vein using 26G needle were injected into 900 cGy irradiated recipient WT mice. The red blood cells in the isolated BM cells from different mice with the same age and gender were removed. A 3×10^5 B16F1 cell suspension in 200 μ L PBS was subcutaneously injected into the right flank of mice at day 20 post transfer. Half of these mice were orally inoculated with 30 μ L 2×10^7 CFU live *C. cladosporioides* suspended in PBS at day 8 post injection. All tumor bearing mice were monitored regularly for reduced feeding, weight loss or dehydration. Tumor sizes were measured every day, and mice were sacrificed when the tumor volume reaches 2000 mm³, as per IACUC limit.

214

215 **Examination of pH values in water containing oral swabs from mice**

216 Mice were inoculated orally with 30 μ L of 2×10^7 CFU *Saccharomyces cerevisiae* (O2240200, 217 obtained from Seyedmojtaba Seyedmousavi's laboratory) or *C. cladosporioides* weekly for eight weeks. 218 Oral pH values were then measured. For each mouse, 500 μ L of sterile distilled water was added to a 1.5 219 mL tube. A cotton swab was soaked into the water, the extra water was squeezed off against the tube wall, 220 and the swab was twirled slowly and thoroughly throughout the oral cavity of the mouse. The cotton swab 221 was rinsed in the water in the 1.5 mL tube several times, and the extra water was squeezed out. The pH of 222 the water in each tube was measured using a small-tipped pH meter (H1981036, Hanna Instruments) and 223 paper pH testing strips (ColorpHast pH Strip, 4.0 to 7.0).

224

225 **Antibodies and human samples**

226 Antibodies used for immunoblotting and immunostaining included STAT3 (sc-293151,
 227 RRID:AB_3717599) and cyclin D1 (sc-717, RRID:AB_631336) from Santa Cruz Biotechnology; α -
 228 tubulin (ab4074, RRID:AB_2288001), uric acid (ab53000, RRID:AB_883382), and HIF-1 α (ab2185,
 229 RRID:AB_302883) from Abcam; NLRP3 (NBP2-12446, RRID:AB_2750946) from Novus Biologicals
 230 Scientific; p-STAT3 (CST-9145s, RRID:AB_2491009), and p-EGFR (CST-2234s, RRID:AB_331701)
 231 from Cell Signaling Technology; HIF-1 α (16H4L13, RRID:AB_2741461) from Thermo Fisher Scientific;
 232 HIF-1 α (700505, RRID:AB_2532327) from Invitrogen; and β -actin (A2228, RRID:AB_476697) from
 233 Sigma-Aldrich. Human HNSCC tissue arrays and sections (HN438b, HN241b, HN811b, HuCAT476,
 234 HuCAT536, T271b, and HuCAT526) were purchased from US Biomax. Human samples were approved
 235 (protocol: 09-H0172) by the National Institute of Allergy and Infectious Diseases Institutional Review
 236 Board and written informed consent was obtained from all patients prior to sample collection (24). Studies
 237 were conducted in accordance with one of the following recognized ethical guidelines: Declaration of
 238 Helsinki, International Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS),
 239 Belmont Report, or U.S. Common Rule. The human SCC cell lines A431 and SCC-25 (CRL-1555 and
 240 CRL-1628, ATCC, RRID:CVCL_0037 and RRID:CVCL_1682) (25) were used in this study.

241

242 **Single-cell RNA sequencing (scRNA-seq)**

243 Freshly and carefully dissected buccal mucosal layers from experimental mice of C57BL/6
 244 background at nine months of age. Totally one pooled wild-type (WT *Ikka*^{fl/fl}) (n=3), two independent
 245 pooled *Ikka*^{ASOE} (n=3 each) and one pooled *Ikka*^{ASOE}*Stat3*^{ASOE} (n=3) samples were minced into small pieces
 246 and incubated in DMEM/F12 with antibiotics, 30 μ g/mL DNaseI, and 3 mg/mL collagenase P for 30

247 minutes at 37 °C with intermittent shaking to dissociate cells. Cells were then filtered through a 70- μ m
248 filter into a new tube (26). Blood samples were collected from mice with or without fungi treatment (five
249 mice per group), and red blood cells were removed by using ammonium-chloride-potassium (ACK) lysis
250 buffer several times. The backs of the mice including one pooled WT (n=3) and one pooled *Ikka* ^{Δ SOE} (n=4)
251 samples with skin tumor lesion were shaved, and the dorsal skin was isolated and floated on HBSS +
252 0.04% BSA. The skin was then cut into smaller pieces (approximately 1 mm in width) and incubated in
253 0.2% collagenase at 37 °C for one hour. Partly digested skin was placed in a 70- μ m cell strainer, smashed
254 with a piston and rinsed three times with HBSS + 0.04% BSA. The flow-through was saved on ice, while
255 the undigested tissue remaining in the cell strainer was incubated in 0.05% trypsin-EDTA for 15 minutes
256 at 37 °C. Trypsin-digested tissue was smashed once more and then passed through a 70- μ m cell strainer.
257 The flow-through of the collagenase digestion (containing mainly stromal cells) and the flow-through of
258 the trypsin digestion (containing mainly epidermal cells) were pooled, spun down, and filtered through a
259 70- μ m cell strainer. Viability of the cell suspension was determined using trypan blue (27).

260 All samples were sent to the Sequencing Facility at the Center for Cancer Research, National Cancer
261 Institute (<https://ncifrederick.cancer.gov/services/accessioning/Services/LabServices/Area/10>). 10 $\times$
262 Genomics Single Cell Gene Expression libraries were sequenced. Primary analysis was performed with
263 Cell Ranger 6.1.2 (RRID:SCR_017344) software under the default parameters. The Seurat v4.0.3 package
264 (RRID:SCR_016341) for R was used to further analyze scRNA-seq data (28). Outliers to the 200–2500
265 read count (nFeature_RNA) were excluded to eliminate doublets and debris. After normalizing and scaling
266 data, we performed a linear dimensional reduction by principal component analysis using the top 2,000
267 most viable genes (FindVariableFeatures). Based on an elbow plot, we selected principal appropriate
268 components to calculate the shared nearest neighbor graph and clustered data using the Louvain algorithm
269 (29) with a resolution of 0.5 using the function FindClusters (30). Clustered data were displayed using

uniform manifold approximation and projection (UMAP) dimensional reduction (RunUMAP function). Clusters were identified using the Seurat function FindAllMarkers for immune populations, and the SingleR package (31) was used to confirm each cluster. The DoHeatmap function was used to show marker genes in clusters of interest. The gene expression profile was presented using the Vlnplot function from the Seurat package. Differential gene expression between two groups was analyzed by DEsingle package (32).

For scoring of biological processes, the biological gene set signature was scored for individual cells using the “AddModuleScore” function from Seurat 4.1. The ROS production, Gelatinase, and Phagocytosis genes were used based on a reported method (33). The calculation was based on the average expression levels of each gene set signature subtracted by aggregated expression of control features set that are randomly selected. scRNA-seq data have been deposited in the NCBI Gene Expression Omnibus (accession number GSE223442 and GSE215966).

282

283 RNA-seq

Fungi (2×10^7 CFU) in 30 μ L PBS were heated at 95 °C for 10 minutes and were used to treat cells. A431 or SCC25 cells were plated into a six-well plate at 5×10^5 cells per well. Cultured cells were collected after treatment with heat-killed *C. cladosporioides* or calphostin C. Bone marrow (BM) cells were flushed from femur/tibia pairs of 8–12-week-old WT C57BL/6 mice with PBS using a 25-gauge needle. Red blood cells were removed using ACK lysis buffer, and cells were washed with PBS. BM neutrophils were isolated with density gradient centrifugation using Histopaque 1119 (density, 1.119 g/mL) (11191, Sigma) and Histopaque 1077 (density, 1.077 g/mL) (10771, Sigma) (34) at 2000 rpm for 30 minutes. After being washed with PBS, neutrophils were seeded in 24-well plates at one million cells per well with 1 mL medium and treated with 10 μ L heat-killed *C. cladosporioides* (approximately 6.7

293 $\times 10^6$) with or without lactic acid (2 mM) or uric acid (10 μ M) overnight in RPMI-1640 medium with 10%
 294 FBS and L-glutamine and 1 $\times$ Penicillin-Streptomycin (Gibco, 15140122). Cells were collected and RNA
 295 was extracted with RNeasy Mini Kit (74104, QIAGEN). Samples were pooled and sequenced on a
 296 NextSeq at the Center for Cancer Research's Sequencing Facility (Frederick, MD21701) by using
 297 Illumina TruSeq Stranded mRNA Library Prep and paired-end sequencing. Sequence data were analyzed
 298 using R package DESeq2/3.1.0 (<https://bioconductor.org/packages/release/bioc/html/DESeq2.html>). For
 299 Gene Set Enrichment Analysis (GSEA) of the RNA-seq data, the list of significant differentially expressed
 300 genes (DEGs) ($\log_{2}FC > 0.4$, $p_{adj} < 0.05$) were ranked by fold change, and KEGG pathway enrichments
 301 and other gene sets were analyzed by GSEA_4.0.3. The enriched pathways for fungus treated DEGs were
 302 selected, and normalized enriched scores (NES) were plotted. Heatmaps were presented according to
 303 related pathways. RNA-seq data were deposited in the NCBI Gene Expression Omnibus (GEO) (accession
 304 number GSE192654 and GSE223080). Fgsea analysis and volcano plot were generated by R packages
 305 based on RNA-seq data.

306

307 Neutrophil extracellular trap visualization

308 Bone marrow (BM) cells were flushed from femur/tibia pairs of 8–12-week-old WT C57BL/6 mice
 309 with PBS using a 25-gauge needle. Red blood cells were removed using ACK lysis buffer, and cells were
 310 washed with PBS. BM neutrophils were isolated by density gradient centrifugation using Histopaque
 311 1119 (density, 1.119 g/mL) (11191, Sigma) and Histopaque 1077 (density, 1.077 g/mL) (10771, Sigma)
 312 (34) at 2000 rpm for 30 minutes. After being washed with PBS, neutrophils were seeded in 24-well plates
 313 at one million cells per well and treated with live *C. cladosporioides* (MOI to neutrophils is 10:1) with or
 314 without lactic acid (2 mM) or uric acid (10 μ M) for 2.5 hours in RPMI-1640 medium with 10% FBS and
 315 L-glutamine and 1 $\times$ Penicillin-Streptomycin (Gibco, 15140122). After incubation, supernatant culture

medium was collected and mixed well and 20 μ L supernatant from each was added into 3 mL of YPD for fungal culture overnight. Then cells were stained with 5 μ M SYTOXTM Green Nucleic Acid Stain (Invitrogen, S7020) in 1 $\times$ HBSS (J67799.K2, Gibco). After staining, round coverslips in the wells were picked out and put onto the slides, and a big drop of anti-fade mounting medium (H-1000-10, Vector Lab) was dropped on the samples and the slides were sealed with a square coverslip and ready for observation under fluorescence microscope. A SmartSpec 3000 spectrophotometer (Bio-Rad Laboratories) was used to measure fungi density at OD₆₀₀ on the next day.

323

324 **Fluorescence *in situ* hybridization (FISH) for fungal staining**

FISH was done on paraffin-embedded human HNSCC tissue array sections (HN241b and HN811b, US Biomax) and human HNSCC tissue sections (HuCAT526, HuCAT536) and fungus-negative control specimens (Fungus 4-Tissue Artificial TMA Aspergillus, Candida, Histoplasma and Negative control, BSB-0335-CS, BioSB). To prevent tissue detachment during antigen retrieval, slides were baked for 60 minutes at 60 °C and then immediately were immersed in xylene two times for 10 minutes each time (fresh xylene each time) and in 100% ethanol two times for 10 minutes each time (fresh ethanol each time), then in 95% ethanol for 10 minutes, and finally in 70% ethanol for 3 hours at 4 °C. Slides were then rinsed in RNase-free 2 $\times$ SSC (AM9763, InvitrogenTM) for 10 minutes, treated with proteinase K solution (10 μ g/ml in 2 $\times$ SSC) for 10 minutes in 42 °C, and were then washed in 2 $\times$ SSC for 5 minutes twice, followed by 2 rinses in wash buffer [2 $\times$ SSC, 15% formamide (F9037, Sigma-Aldrich)] for 5 minutes each. For Hybridization, D223 28S rRNA gene probe (5'-CCACCCACTTAGAGCTGC-3') labeled with Cy3 or FAM fluorophore (Cy3 λ_{ex} = 555 nm; λ_{em} = 569 nm; FAM: λ_{ex} = 493 nm, λ_{em} = 517 nm) was used to detect the fungal signals in the tissues. Slides were incubated with the 1 μ M probe in hybridization buffer [(2 $\times$ SSC, 10% dextran sulfate (D8906, Sigma-Aldrich), 1 mg/mL salmon sperm DNA, 15% formamide,

339 0.02% BSA, 2mM vanadyl ribonucleoside (S1402S, New England Biolabs)] at 30 °C overnight in the
340 humidified chamber of an incubator and then were washed in the wash buffer at 30 °C for 30 minutes.
341 Samples were counterstained with VECTASHIELD® PLUS Antifade Mounting Medium with DAPI (#H-
342 2000-10, Vector Laboratories). Slides were visualized under a confocal fluorescent microscope (Leica
343 SP8 Laser Confocal Microscope).

344

345 **Co-detection of RNAscope and immunofluorescent staining**

346 Paraffin-embedded human HNSCC tissue sections (HN438b, HuCAT536 and HuCAT526, US
347 Biomax), RNAscope with RNAscope® 2.5HD Detection kit (RED), and immunofluorescent staining
348 were used for the co-detection. Slides were baked in a dry air oven at 60 °C for 60 minutes then incubated
349 in xylene twice (5 minutes each time) and 100% ethanol twice (1 minute each time). After air drying,
350 slides were incubated with RNAscope® hydrogen peroxide for 10 minutes at room temperature and
351 washed with distilled water. Slides then were submerged into hot 1× co-detection target retrieval solution
352 for 15 minutes at 98-102 °C and washed with distilled water and 1× PBS-T, and then moved up and down
353 3-5 times. Then 10 µg/mL Myeloperoxidase/MPO Antibody (#AF3667, R&D, RRID:AB_2250866) or
354 Myeloperoxidase/MPO Antibody with 0.3 µg/mL Cladosporium Antibody (OX-CH1, DSHB Hybridoma,
355 RRID:AB_2617415) diluted in co-detection antibody diluent was dropped on the slides and then the slides
356 were placed in humidity tray and incubated at 4 °C overnight. Following antibody incubation, slides was
357 washed by PBS-T twice and, submerged in 10% neutral buffered formalin (NBF) for 30 minutes in a fume
358 hood, and then were washed by PBS-T. Slides were treated with 2-4 drops of RNAscope® protease plus
359 and were incubated in the HybEZ™ Oven at 40 °C for 30 minutes. After washing, slides were proceeded
360 to RNAscope® protocol starting with IL-1β probe hybridization and ending with development of RED
361 solution. Slides were washed by 1×wash buffer and incubated with co-detection blocker for 15 minutes at

362 40 °C. Second antibody of anti-goat IgG (H+L) Alexa Fluor™ 488 (#A-11055, Invitrogen,
 363 RRID:AB_2534102) or anti-goat IgG (H+L) Alexa Fluor™ 488 with anti-mouse IgG (H+L) Alexa
 364 Fluor™ 647 (A-21235, Invitrogen, RRID:AB_2535804) diluted in co-detection antibody diluent was
 365 added to the sections, which were then incubated for 60 minutes at room temperature. Slides were washed
 366 by PBS-T twice for 2 minutes, counterstained by VECTASHIELD® Antifade Mounting Medium with
 367 DAPI (#H-1200-10, Vector Laboratories), and finally sealed by a coverslip. Slides were visualized under
 368 a confocal fluorescent microscope (Leica SP8 Laser Confocal Microscope).

369

370 Immunoblotting

371 Cell lysates and protein extracts from tissues were applied to an acrylamide gel, and protein levels
 372 were measured by immunoblotting with specific antibodies. In brief, a lysate (10–50 µg) was dissolved in
 373 a protein gel loading buffer (Bio-Rad Laboratories), heated at 95 °C for 5 minutes, and resolved using 7–
 374 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Separated proteins were
 375 transferred to a polyvinylidene difluoride (PVDF) membrane (Immobilon-P, MilliporeSigma), blocked in
 376 5% nonfat milk, and analyzed using the indicated primary and secondary antibodies. Proteins were
 377 detected using a chemiluminescence reagent (NEL104001EA, PerkinElmer). Human SCC A431 or
 378 SCC25 cells or murine cell line B16F1 were treated with heat-killed or live *C. Cladosporioides* or
 379 calphostin C (15383, Cayman Chemical) at a concentration of 10 nM, heat-killed *Saccharomyces*
 380 *cerevisiae*, heat-killed *Ramularia spp.* (P4211973, obtained from Seyedmojtaba Seyedmousavi's
 381 laboratory), IL-1β (10 ng/mL), IL-17A (10 ng/mL), and GW2974 (10 µM, G0668, Sigma-Aldrich) or
 382 osimertinib (AZD9291, 5 µM; Selleck Chemicals) at different time courses. Protein levels were examined
 383 by immunoblotting with antibodies against p-EGFR, EGFR, p-STAT3, STAT3, cyclin D1, HIF-
 384 1α, NOX2 or β-actin.

Neutrophils isolated from bone marrow were seeded in 24-well plates at one million cells per well and treated with heat-killed *C. cladosporioides* with or without lactic acid for three different time courses in RPMI-1640 medium with 10% FBS and L-glutamine and 1× Penicillin-Streptomycin (Gibco, 15140122). Cells were washed, centrifuged at 1000 g for 5 minutes, and resuspended in high-salt cell lysis buffer for 45 minutes on ice. Protein was quantified using Pierce BCA Protein Assay Kit (23225, Thermo Scientific).

390

391 **RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)**

Total RNA was isolated from A431 cells and SCC25 cells using RNeasy Mini Kit (74104, QIAGEN). Complementary DNA (cDNA) was synthesized with a Tetro cDNA Synthesis Kit (BIO-65043, Bioline). For quantitative real-time polymerase chain reaction (qRT-PCR), genes of interest were examined with the PowerUp™ SYBR™ Green Master Mix (A25742, Applied Biosystems) and ABI Prism 7300 Detection System (4304437, Applied Biosystems) according to the manufacturer's instructions. PCR primers included human *STAT3* (Forward: CAGCAGCTTGACACACGGTA, Reverse: AAACACCAAAGTGGCATGTGA), *IL1B* (Forward: ATGATGGCTTATTACAGTGGCAA, Reverse: GTCGGAGATTCGTAGCTGGA), *CCND1* (Forward: GCTGCGAAGTGGAAACCATC, Reverse: CCTCCTTCTGCACACATTTGAA), *HIF1A* (Forward: GAACGTGCGAAAAGAAAAGTCTCG, Reverse: CCTTATCAAGATGCGAACTCACA), *HK2* (Forward: TGCCACCAGACTAAACTAGACG, Reverse: CCCGTGCCCACAATGAGAC), *JUN* (Forward: TCCAAGTGCCGAAAAAGGAAG, Reverse: CGAGTTCTGAGCTTTCAAGGT), and *TRIB3* (Forward: AAGCGGTTGGAGTTGGATGAC, Reverse: CACGATCTGGAGCAGTAGGTG), all from Integrated DNA Technologies. Gene expression was normalized to expression level of the β -actin housekeeping gene, *ACTB* (Forward: CATGTACGTTGCTATCCAGGC, Reverse:

407 CTCCTTAATGTCACGCACGAT). Data were analyzed by the $\Delta\Delta C_t$ method and were expressed as a
408 fold-change in mRNA expression relative to control values.

409 For the Real-time PCR to detect *Cladosporium cladosporioides* in paraffin-embedded human cancer
410 specimens, briefly, paraffin-embedded tissue sections of human cancer (HuCAT476, HuCAT471,
411 HuCAT481, HuCAT526, HuCAT531, HuCAT536, HuCAT541) were collected and transferred to sterile
412 Eppendorf tubes in biosafety level II hood and soaked in 1mL xylene/tube for 1 hour at room temperature,
413 followed by three washes with 100% ethanol, 75% ethanol, and sterile 1× PBS, respectively. Tissue
414 samples and human cell lines (A549, SCC25, A431) were then subjected to overnight digestion in tissue
415 lysis buffer (100 mM Tris-HCL pH 8.0, 200 mM NaCl, 2mM EDTA, 0.2% SDS, 200 µg/mL proteinase
416 K) at 0.3 mL/sample. After digestion, genomic DNAs were extracted using one volume of
417 phenol:chloroform:isopropanol alcohol (77176, Sigma-Aldrich) at 25:24:1 according to the commercial
418 manual. For *Cladosporium* real-time PCR, 300 ng/sample DNA was used and real-time PCR was
419 performed using *Cladosporium cladosporioides* TaqMan PCR Detection Kits (TM33050, Norgen Biotek)
420 with Specific Primer and Probe mix as well as *C. cladosporioides* positive DNA control in the kit and 100
421 ng/sample DNA was used as negative control by using PowerUp™ SYBR™ Green Master Mix with
422 GAPDH primer of human genomic DNA (*Forward*: GTCAAGGCTGAGAACGGGAA, *Reverse*:
423 AGCCACACCATCCTAGTTGC). Since there is no amplification of negative samples (no C_t value),
424 relative quantification was measured by $2^{-\Delta C_t}$.

425

426 **Immunohistochemical and immunofluorescent staining**

427 The Histology and Tissue Core Facility at the Frederick National Laboratory for Cancer Research, as
428 well as Histoserv (Germantown, MD, 20874), prepared paraffin sections of mouse organs and performed
429 hematoxylin and eosin (H&E) staining and immunohistochemical (IHC) staining for p-STAT3, cyclin D1,

430 HIF-1 α , F4/80 (macrophages), Foxp3 (regulatory T cells), keratin 5 and Ki-67. Slides were baked at 60
431 °C for 1 hour before experiment. Immunofluorescent staining of other antibodies was performed on
432 paraffin sections of murine oral cavity, human HNSCC tissue sections and fungus-negative human lung
433 tissue (same as before) as well normal tissues. In brief, slides were deparaffinized and rehydrated using
434 the following protocol: Xylene for 10 minutes twice, 100% ethanol for 5 minutes, 95% ethanol for 5
435 minutes, 70% ethanol for 5 minutes and three washes in PBS for 2 minutes each. Then endogenous
436 peroxidase quenching was performed by using Peroxide Blocking Reagent (927402, BioLegend) for 30
437 minutes, followed by Target Retrieval Solution (S236784-2, DAKO) for 10 minutes at 95 °C. Slides were
438 left to cool at room temperature and then washed three times in PBS. Blocking was done with 1% BSA
439 and 0.2% Triton in PBS for 60 minutes at room temperature. Slides were then incubated overnight at 4 °C
440 with primary antibodies against NLRP3 (NBP2-12446, RRID:AB_2750946), p-EGFR (CST-2234s,
441 RRID:AB_331701) or uric acid (ab53000, RRID:AB_883382) or with anti-Cladosporium antibody (OX-
442 CH1, DSHB Hybridoma, RRID:AB_2617415). Sections were then washed and stained with the
443 fluorescence-conjugated secondary antibodies for one hour at room temperature. Finally, sections were
444 mounted with VECTASHIELD® Antifade Mounting Medium with DAPI (#H-1200-10, Vector
445 Laboratories). Immunofluorescent staining was visualized, and cells were photographed under a
446 fluorescence microscope (Nikon Eclipse E800, Nikon Instruments) or a confocal fluorescent microscope
447 (Leica SP8 laser confocal microscope). Numbers of macrophages and Treg cells were statistically
448 analyzed by counting positive IHC-stained cells in the same numbers of views in each section from each
449 group. Each group contained three to four mice. IHC staining intensity for p-STAT3, cyclin D1, and HIF-
450 1 α was determined by Image J software.

451

452 **Bead-based flow cytometry for cytokines from serum**

453 All blood samples were collected in nonheparinized tubes and allowed to clot at room temperature
454 (RT) for one hour and then centrifuged at 1,000 g for 10 minutes at room temperature. Serum samples
455 were absorbed from the coagulated blood, aliquoted, and stored at -80°C . BioLegend LEGENDplex
456 (Mouse Inflammation Panel Mix and Match panel, #740446) bead-based immunoassays were used to
457 analyze 13 mouse cytokines, including IL-1 α , IL-1 β , IL-6, IL-10, IL-12p70, IL-17A, IL-23, IL-27, MCP-
458 1, IFN- β , IFN- γ , TNF- α , and GM-CSF according to the manufacturer's instructions. In brief, 25 μL of
459 each serum sample, diluted twofold with assay buffer, were added into 25 μL of mixed beads and an assay
460 buffer solution in the wells. The plate was then covered with a plate sealer and placed on a plate shaker at
461 800 rpm for two hours at room temperature. After one wash with 1 $\times$ washing buffer to remove unbound
462 proteins, 25 μL of detection antibodies were added to each well. The plate was then covered with a plate
463 sealer and shaken at 800 rpm for one hour at room temperature. Without washing the plate, 25 μL of SA-
464 PE antibodies were added to each well. The plate was then covered with a plate sealer and shaken at
465 800 rpm for another 30 minutes at room temperature. After one wash with 1 $\times$ washing buffer, samples
466 were suspended with wash buffer and analyzed on a flow cytometer. Data were calculated and collected
467 using the LEGENDplex data analysis software (BioLegend).

468

469 Flow cytometry

470 Freshly dissected oral buccal and skin samples, and bone marrow neutrophils were isolated as
471 described above. Blood cells were collected from WT C57BL/6 mice (8–12 weeks old) in heparin tubes,
472 and red blood cells were removed by several times with ACK lysis buffer. White blood cells were seeded
473 in a 24-well plate and treated with 10 μL heat-killed *C. cladosporioides* (approximately 6.7×10^6 CFU)
474 and lactic acid (2 mM) or uric acid (10 μM) overnight in RPMI-1640 medium with 10% FBS and L-
475 glutamine. All cell samples were collected for flow cytometric analyses. For the ROS determination, cells

476 were stained with DHR123 (Dihydrorhodamine 123, Sigma-Aldrich D1054, 10 μ M) in 100 μ L PBS in a
477 37°C incubator for 10 minutes (protected from light). After staining, cells were blocked with rat serum in
478 flow buffer (2 mM EDTA and 0.1% BSA in PBS) for 5 minutes, and then washed, and resuspended in
479 PBS with LIVE/DEAD Fixable Violet Dead Cell Stain kit for 30 minutes at 4°C in dark. Then cells were
480 stained with PE-eFluor™ 610-CD45 antibody (61-0451-82, Invitrogen, RRID:AB_2574555), PE-Ly-6G
481 antibody (101207, BioLegend, RRID:AB_312790), APC-F4/80 antibody (17-4801-82, eBioscience,
482 RRID:AB_2784648), PE- Cyanine7-CD11b antibody (101215, BioLegend, RRID:AB_312798) for 30
483 minutes at 4 °C after one time wash with PBS. For IL-1 β staining, cells were blocked in the same way and
484 stained with LIVE/DEAD™ Fixable Green Dead Cell Stain kit for 30 minutes at 4°C in dark. Then, Cells
485 were stained with PE-eFluor 610-CD45 antibody (61-0451-82, Invitrogen, RRID:AB_2574555), APC
486 anti-mouse CD326 (Ep-CAM) antibody (118213, BioLegend, RRID:AB_1134105) or APC-F4/80
487 antibody (17-4801-82, eBioscience, RRID:AB_2784648), Pacific Blue™ Ly-6G antibody (127612,
488 BioLegend, RRID:AB_2251161), and PE-Cy7-CD11b antibody (101215, BioLegend,
489 RRID:AB_312798) for 30 minutes at 4 °C, washed with PBS, and fixed in fixation buffer from staining
490 buffer kit (00-5523-00, eBioscience) for 40 minutes. After washing with 1 $\times$ permeabilization buffer, cell
491 samples were stained with antibodies for biotin anti-mouse and rat IL-1 β antibody (503505, BioLegend,
492 RRID:AB_2295906) in 1 $\times$ permeabilization buffer at room temperature for 30 minutes, washed, and
493 stained with streptavidin PE conjugate antibody (12-4317-87, Invitrogen) for another 30 minutes at room
494 temperature. Finally, cells were washed, resuspended in flow buffer, and analyzed with flow cytometry.
495 For lymphocytes detection, cell samples were stained with LIVE/DEAD™ Fixable Violet Dead Cell Stain
496 Kit (L34955, Invitrogen), and then with the appropriate antibodies including PE-Cyanine7-CD3e antibody
497 (25-0031-82, eBioscience, RRID:AB_469572), PE-eFluor 610-CD45 antibody (61-0451-82, Invitrogen,
498 RRID:AB_2574555), Brilliant Violet 785™ CD4 Antibody (100453, BioLegend, RRID:AB_2565843),

499 PerCP/Cyanine5.5 CD8a Antibody(100734, BioLegend, RRID:AB_2075238) at 4 °C for 30 minutes.

500 Stained cells were washed with PBS and fixed in fixation buffer from the staining buffer kit (00-5523-00,

501 For reversed-phase ion-pairing LC-MS² assay for measuring glycolysis and intermediate metabolites,

502 all reference standards compounds (TGP) were obtained from Sigma-Aldrich (St. Louis, MO). Stable

503 isotope-labeled internal standards (SI-TGP) 13C₆-glucose-6-phosphate, and 13C₆-fructose-1,6-

504 bisphosphate) were purchased from Medical Isotopes. All analytical standards have reported chemical

505 and isotopic purity of ≥98% and were used without further purification. OmniSolv[®] LC-MS grade

506 acetonitrile and methanol were obtained from EMD Millipore. Tributylamine (TBA), LC-MS grade acetic

507 acid, and formic acid were purchased from Fisher Scientific. All chemicals and solvents used in this study

508 were HPLC or reagent.

509 A431 and SCC25 cells were seeded into a six-well plate at 5 × 10⁵ cells per well in triplicates and then

510 treated with 30 μL heat-killed *C. cladosporioides* and 10 nM calphostin C. Cells were washed with PBS

511 and then collected by scraping into PBS followed by centrifugation. Metabolites were extracted in 500 μL

512 of chilled 80% methanol. Sample was vortexed vigorously for 30 s and centrifuged at 14,000g for 10 min.

513 Fifty microlitre supernatant was transferred to an autosampler vial containing 50 μL 10 μM SI-TGP

514 methanol solution. Sample was dried with the SpeedVac[®] vacuum concentrator (Thermo Fisher

515 Scientific) and then reconstituted in 60 μL 3% (v/v) methanol in water. For glucose measurement, samples

516 were derivatized with 3-nitrophenylhydrazine.

517 Ten microlitre sample was injected for reversed-phase ion-pairing LC-MS² analysis, performed on

518 Thermo TSQ[™] Quantiva triple quadrupole mass spectrometer (Thermo Scientific) coupled with a

519 NexeraXR LC system (Shimadzu Scientific Instruments). Both the HPLC and mass spectrometer were

520 controlled by Xcalibur[™] software (Thermo Scientific). The chromatography was carried out on a 100-mm

521 long × 2.1-mm i.d. Synergi Hydro-RP C18 column with 2.5 μm particles and 100Å pore size

(Phenomenex) kept at 40°C. The mobile phase, operating at a flow rate of 200 µL/min, consisted of 10 mM TBAA in water as solvent A and methanol as solvent B. For the analysis the linear gradient stayed at B/A solvent ratio 3:97 for 3 min and then the B/A solvent ratio was changed from 3:97 to 80:20 in 14 min. After washing with 98% B for 3 min, the column was re-equilibrated with a mobile phase composition B/A of 3:97 for 10 min before the next injection. The general MS settings were as follows: source: ESI; ion polarity: negative; spray voltage: 2500 V; sheath and auxiliary gas: nitrogen; sheath gas pressure: 40 arbitrary units; auxiliary gas pressure: five arbitrary units; ion transfer capillary temperature, 350°C; scan type: selected reaction monitoring; collision gas: argon; collision gas pressure: 2 mTorr. Quantitation of the selected metabolites was carried out using Xcalibur™ Quan Browser (Thermo Scientific). Calibration curves for each metabolite were constructed by plotting TGP/SI-TGP peak area ratios obtained from calibration standards and fitting the data using linear regression with 1/X weighting. The metabolite concentrations in the samples were then interpolated using this linear function.

For examination of lactate in cell culture supernatant, the collected culture medium from A431 cells with and without treatment (as described above) was stored at -80 °C to inactivate endogenous lactate dehydrogenase. The lactate level in 50 µL of cell culture supernatant from each sample was analyzed using a Lactate Colorimetric Assay Kit II (K627-100, BioVision). The experimental procedure followed the kit's instruction. Oral swab solution from the mouth of mice was also used to detect lactate levels with the same kit.

540

541 **Analysis of scRNA-seq data of human normal and HNSCC Samples**

Human scRNA-seq data were obtained from GEO database (GSE139324), including the tissue resident immune cell samples from 5 healthy donor tonsils and the tumor infiltrating immune cell samples from 26 HNSCCs. Additional Human scRNA-seq data were obtained from GSE164690, including CD45⁺

cell samples from 18 treatment naïve HNSCC patients. The Seurat v4.0.3 package (28) for R was used to analyze scRNA-seq data as above. Tumor stage information was obtained from their table. A neutrophil cluster was a subset from the data identified by using markers, including S100A8 and others. *IL1B* and other gene expression between healthy donors and HNSCCs in neutrophils and macrophages were compared and visualized by ggplot with “stat_compare_means” function to show *P* value in the plots. Further, HNSCC samples were divided into two groups based on the median expression levels of *IL1B*. The gene expression with specific signature scores (such as, sets of differentially expressed genes), including ROS (“CYBA”, “CYBB”, “CYP1A1”, “CYP1A2”, “CYP1B1”, “DDAH1”, “DUOX1”, “DUOX2”, “GBF1”, “HSP90AA1”, “MPO”, “NCF1”, “NOS1”, “NOS2”, “NOS3”, “P2RX4”, “RORA”, “SLC7A2”, “SOD1”, “SOD2”, “SPR”) and PHAGOCYTOSIS (“ABCA1”, “ADGRB1”, “AIF1”, “ARHGAP12”, “ARHGAP25”, “BECN1”, “BIN2”, “CDC42”, “CLCN3”, “ELMO1”, “FCER1G”, “FCGR1”, “FCGR3”, “GSN”, “GULP1”, “IGLL1”, “ITGAM”, “ITGB2”, “MARCO”, “MEGF10”, “MFGE8”, “MSR1”, “MYH9”, “RAC1”, “RAC3”, “RHOBTB1”, “RHOBTB2”, “SH3BP1”, “SIRPA”, “THBS1”, “TREM2”, “TREML4”, “VAMP7”, “XKR4”, “XKR6”, “XKR7”, “XKR8”, “XKR9”) was compared to *IL1B*^{low} or *IL1B*^{high} neutrophils, respectively. ‘FindAllMarkers’ function was used to compare the differential gene expression between *IL1B*^{low} and *IL1B*^{high} neutrophils in HNSCC samples. Macrophage cluster was identified by using markers, including CSF1R and others. The TAM signature scores in macrophage were compared between HD and HNSCC or different stages of HNSCC (“CD163”, “CSF1R”, “TREM2”, “SPP1”, “GPNMB”, “LGALS3”, “VSIG4”, “CD14”, “FOLR2”, “APOE”).

565

566 Quantification and statistical analysis

Statistical parameters, including the exact n value that represents number of mice per group, dispersion and precision measures (mean $\pm$ SEM or SD), and statistical significance, are reported in the figures and figure legends. Data were judged to be statistically significant when $P < 0.05$ by the selected statistical analysis method: two-tailed Student's t -test for comparison between two groups, as well as Fisher's exact test, Chi-squared (χ^2) test, and the log-rank test. In figures, asterisks denote statistical significance as calculated by the selected statistical analysis method (* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$). Statistical analysis was performed in GraphPad Prism 6.

Data Resources and Data and Materials Availability

The mRNA expression data in human HNSCCs were downloaded from TCGA using cBioPortal (<https://www.cbioportal.org/>). TCGA RNA-seq data in human HNSCC data sets for the correlation analyses were downloaded from the Broad GDAC Firehose (<https://gdac.broadinstitute.org/>). Human scRNAseq data were obtained from GEO at GSE139324 and GSE164690. The scRNA-seq data generated in this study have been deposited in the NCBI GEO under accession numbers GSE223442 and GSE215966. The RNA-seq data generated in this study were deposited in the NCBI GEO under accession numbers GSE192654 and GSE223080. All other raw data generated in this study are available upon request from the corresponding author.

RESULTS

Advanced human HNSCCs exhibit increased fungal burden and infiltration of *IL1B*-High neutrophils with reduced phagocytic and oxidative gene Signatures, along with *IL1B*-High TAM

589 The oral cavity is a primary entry site for environmental microbes, where innate immune resistance is
590 essential for restraining their expansion; however, the impact of fungal interactions with innate immune
591 cells on the TME and oral carcinogenesis remains largely uncharacterized. We first performed Periodic
592 Acid-Schiff staining, which revealed fungal elements in human HNSCC sections (Supplementary Fig.
593 S1A). Fluorescence in situ hybridization (FISH) using a pan-fungal probe confirmed higher fungal
594 abundance in HNSCC and adjacent SCC tissues compared with healthy HN tissue controls (Fig. 1A and
595 B; Supplementary Fig. S1B). Stronger signals were observed in stage III–IV than in stage I–II HNSCCs.
596 We next analyzed DNA from paraffin-embedded sections of 20 stage II–IV HNSCC cases (16 larynx, 3
597 oral cavities, and 1 tongue) using internal transcribed spacer (ITS) rRNA gene sequencing, identifying
598 multiple fungal taxa in each sample (Fig. 1C; Supplementary Fig. S1C). Most identified fungi were
599 environmental species, with *Cladosporium spp.* and *C. cladosporioides* detected in 14 and 13 of 20
600 samples, respectively. PCR with species-specific primers further confirmed the presence of *C.*
601 *cladosporioides* in tumor samples but not in pathogen-free human tumor cell lines used as negative
602 controls (Supplementary Fig. S1D). Finally, immunofluorescence (IF) staining with a *Cladosporium*-
603 specific antibody showed significantly higher fungal signals in HNSCCs compared with healthy HN
604 tissues, fungi-free human lungs, and *Candida*- or *Aspergillus*-positive rat lungs (Fig. 1D; Supplementary
605 Fig. S1E and S1F).

606 We analyzed CD45⁺ infiltrating hematopoietic cells in tumor tissues from 26 HNSCC patients and in
607 tonsils from 5 healthy donors (HD) using publicly available single-cell (sc)RNA-seq data (Fig. 1E;
608 Supplementary Fig. S2A and S2B). Cluster 5, comprising neutrophils characterized by high expression of
609 *S100A8*, *SOD2*, and *CSF3R*, showed high *IL1B* and *CYBB* expression (Fig. 1F; Supplementary Fig. S2C)
610 (33,35,36). *IL1B* expression was higher in HNSCC-derived neutrophils than in HDs (Fig. 1F, right).
611 Neutrophils were stratified into *IL1B*-High and *IL1B*-Low groups based on median expression

612 (Supplementary Fig. S2D). Compared with *IL1B*-Low cells, *IL1B*-High neutrophils from HNSCCs
613 exhibited reduced expression of *CYBB* and *CYBA* and reduced ROS and phagocytosis gene signatures, but
614 increased expression of inflammatory genes, including *NLRP3* (24), *NFE2L2*, *CD44*, and other encoding
615 multiple cytokines, chemokines, and inflammation regulators (Fig. 1G and H; Supplementary Fig. S2E).
616 In contrast, no significant differences in these signatures were observed between *IL1B*-High and *IL1B*-
617 Low neutrophils from HDs (Fig. 1G; Supplementary Fig. S2E, left). Similar patterns were confirmed in
618 an additional cohort of 18 human HNSCC samples (Supplementary Fig. S2F–S2H).

619 Concurrently, the tumor-associated macrophage (TAM) signature score (37) was significantly higher
620 in macrophage from HNSCC than in those from healthy HN controls (Fig. 1I; Supplementary Fig. S2I).
621 Neutrophils from advanced HNSCC (stage III and IV) exhibited higher *IL1B* but lower *CYBB* expression
622 and ROS and phagocytosis gene signatures compared with those from early-stage tumors (Fig. 1J).
623 Consistently, both the TAM signature score and *IL1B* expression were increased in advanced versus early-
624 stage HNSCCs, although *IL1B* expression in macrophages showed only a trend toward elevation relative
625 to healthy tissues (Fig. 1K; Supplementary Fig. S2J, right, and S2K), indicating that TAMs are enriched
626 in HNSCC and that *IL1B* expression in both neutrophils and TAMs increases with tumor progression.

627 RNAscope corroborated higher *IL1B* expression in HNSCCs compared with healthy HN controls
628 (Supplementary Fig. S3A). In the *IL1B*-rich regions of HNSCC, neutrophils and *IL1B* expression were
629 co-localized with fungal signals, as examined by spatial RNAscope, FISH, immunohistochemical (IHC),
630 and IF staining (Fig. 1L; Supplementary S3B–S3D). The HNSCC patients with *IL1B*-High neutrophil
631 signature showed shorter overall survival compared to patients with *IL1B*-Low signature (Fig. 1M, left).
632 The *IL1B* signature and *STAT3* expression were positively correlated in HNSCCs (Fig. 1M, right).

633

634 **Chronic oral *C. cladosporioides* infection promotes epithelial *Ikka* deletion-initiated oral**
 635 **carcinogenesis and is associated with increased intratumor IL-1 β ⁺ neutrophils and elevated serum**
 636 **IL-1 β and IL-17A in a STAT3-dependent manner**

637 We established an experimental HNSCC mouse model to evaluate the role of *C. cladosporioides*
 638 infection in tumorigenesis. Since ablation of *Ikka* with K15.Cre^{PR1} drives spontaneous skin SCC in *Ikka*^{ff}
 639 mice, we deleted *Ikka* or *Ikka/Stat3* in K15-expressing skin and oral epithelial stem cells (Δ SOE) by topical
 640 RU486 administration to *Ikka*^{ff};K15.Cre^{PR1} and *Ikka*^{ff}*Stat3*^{ff};K15.Cre^{PR1} mice (Fig. 2A) (21,38). Mice
 641 were then orally inoculated weekly with *C. cladosporioides* or vehicle control for four months. *Ikka* ^{Δ SOE}
 642 mice developed oral papilloma and SCC in situ, with increased incidence following fungal inoculation,
 643 whereas WT mice remained tumor-free regardless of exposure (Fig. 2B and C). Concurrent *Stat3* deletion
 644 abolished oral carcinogenesis in both inoculated and control *Ikka* ^{Δ SOE}*Stat3* ^{Δ SOE} mice (Fig. 2B and C),
 645 indicating that both *Ikka* loss-initiated and fungus-enhanced tumorigenesis are STAT3 dependent, and that
 646 STAT3 acts as a key downstream effector of IKK α loss in epithelial cells (20). Oral epithelial cells from
 647 *Ikka* ^{Δ SOE} mice exhibited increased phosphorylated (p)-STAT3, cyclin D1 (a STAT3's target) (39), K5,
 648 Ki67, and p-EGFR compared with WT and *Ikka* ^{Δ SOE}*Stat3* ^{Δ SOE} mice (Fig. 2D; Supplementary Fig. S4A–
 649 S4C). IF staining further showed that the early tumor lesion invading the oral mucosa in *Ikka* ^{Δ SOE} mice
 650 lacked IKK α expression and exhibited elevated p-STAT3, whereas adjacent tissues were positive for
 651 IKK α and negative for p-STAT3 (Supplementary Fig. S4D).

652 Consistent with the findings in mice, human HNSCCs exhibited higher expression of cyclin D1 and
 653 p-STAT3 than healthy controls (Supplementary Fig. S4E). In contrast, a greater proportion of HNSCCs
 654 showed reduced expression of *CHUK*, which encodes IKK α , than increased expression (Supplementary
 655 Fig. S4F, left). Patients with hemizygous *CHUK* deletion and gain/amplification of *CCND1*, which
 656 encodes cyclin D1, had poorer survival than those with diploid status for both genes (Fig. 2E). Elevated

657 *EGFR* or *STAT3* expression was also associated with poorer survival (Fig. 2F). Approximately 40% of
 658 HNSCCs overexpressed *EGFR*, and *EGFR* expression correlated with *STAT3* and *CCND1* levels
 659 (Supplementary Fig. S4F, right, and S2G). These findings indicate that human and mouse HNSCCs share
 660 similar molecular features.

661 Following *C. cladosporioides* infection, fungal colonization increased in the oral cavity of infected
 662 *Ikka*^{ASOE} mice, but not in fungus-infected WT or *Ikka*^{ASOE}*Stat3*^{ASOE} mice, nor in uninfected WT, *Ikka*^{ASOE},
 663 or *Ikka*^{ASOE}*Stat3*^{ASOE} mice (Fig. 2G; Supplementary Fig. S4H). These findings suggest that enhanced
 664 colonization requires epithelial *STAT3* signaling and a permissive TME. This increased fungal burden
 665 also correlated with greater infiltration of neutrophils and macrophages than in the other groups
 666 (Supplementary Fig. S4I). *C. cladosporioides* infection also increased IL-1 β ⁺ neutrophils, IL-17A⁺CD4⁺
 667 cells, and IL-1 β ⁺ EpCAM⁺ oral buccal epithelial cells, while reducing ROS⁺ neutrophils in *Ikka*^{ASOE} mice
 668 relative to WT and *Ikka*^{ASOE}*Stat3*^{ASOE} mice (Fig. 2H; Supplementary Fig. S4J). Moreover, serum IL-1 β
 669 and IL-17A levels were elevated in infected *Ikka*^{ASOE} mice compared with infected WT and
 670 *Ikka*^{ASOE}*Stat3*^{ASOE} mice (Fig. 2I), indicating that oral fungal infection can exert a systemic effect *in vivo*.

671 Infection-induced tissue damage can lead to uric acid (UA) release, which activates inflammasomes
 672 and promotes IL-1 β production (24,40). Oral *C. cladosporioides* inoculation increased levels of UA and
 673 NLRP3 in the oral tissues of *Ikka*^{ASOE} mice compared with uninfected *Ikka*^{ASOE} mice (Fig. 2J and K;
 674 Supplementary Fig. S4K). In contrast, *Stat3* ablation significantly reduced oral UA and NLRP3 levels in
 675 *Ikka*^{ASOE}*Stat3*^{ASOE} mice, regardless of *C. cladosporioides* infection. Consistently, copy number gains of
 676 *NLRP3* were observed in 136 of 488 HNSCC samples, and *NLRP3* expression positively correlated with
 677 *IL1B* expression (Fig. 2L; Supplementary Fig. S4L). Collectively, these data suggest that human and
 678 mouse HNSCCs share similar TME features, including increased IL-1 β ^{High} and ROS^{Low} neutrophils and
 679 the presence of fungi.

680 To characterize neutrophil responses to oral *C. cladosporioides* infection, we performed scRNA-seq
 681 of buccal mucosa, skin, and blood from infected WT, *Ikka*^{ASOE}, and *Ikka*^{ASOE}*Stat3*^{ASOE} mice (Fig. 3A–C;
 682 Supplementary Fig. S5A and S5B). UMAP identified cluster 12 as a population of oral cells expressing
 683 neutrophil markers including *Sl00a8*, *Cxcr2*, and *Ly6g*. This cluster comprised two distinct subsets: one
 684 with high *Cybb* (encoding NOX2), and *Cd177* expression (41) but low *Il1b*, *Nlrp3*, and *Myd88* expression;
 685 and the other showing the opposite pattern with high *Il1b*, *Nlrp3*, and *Myd88* but low *Cybb* and *Cd177*
 686 (Fig. 3B and C). Based on *Il1b* expression, re-clustering of neutrophils identified five subsets (clusters 0
 687 to 4), defined as 0-*Il1b*^M, 1-*Il1b*^{HIGH-1}, 2-*Il1b*^{LOW-1}, 3-*Il1b*^{HIGH-2}, and 4-*Il1b*^{LOW-2} (Fig. 3D). Cluster 0 co-
 688 expressed *Il1b* and *Cybb* (Fig. 3D and E). In WT mice, most neutrophils belonged to cluster 0 or *Il1b*^{LOW}
 689 clusters (2 and 4) (Fig. 3E–G). In contrast, *Il1b*^{HIGH} clusters (1 and 3), enriched for CC and CXC
 690 chemokines, chemokine receptors, and inflammatory regulators including *Nlrp3* and *Nlrp2*, were
 691 predominantly expanded in *Ikka*^{ASOE} mice (Fig. 3E–G). Notably, *Stat3* deletion in *Ikka*^{ASOE} mice restored
 692 neutrophil cluster distributions to a pattern resembling that of WT mice (Fig. 3G).

693 Reactome pathway analysis revealed that oral neutrophils from infected *Ikka*^{ASOE} mice were enriched
 694 for IL-1 β , inflammasome, p75NTR signaling, and innate immune response pathways, but showed reduced
 695 enrichment of phagocytosis, host defense, and ROS production pathways compared with neutrophils from
 696 infected WT mice (Fig. 3H). Consistent with these findings, oral neutrophils from *Ikka*^{ASOE} mice showed
 697 higher expression of genes linked to IL-1 β signaling and myeloid activation, including *Nlrp3*, *Il1b*, *Myd88*,
 698 *Ccl6*, and *Atf3*, and lower levels of genes involved in host-defense functions, including *Capg*, *Ltf*, *Camp*,
 699 *Lcn2*, and *Cybb* (Fig. 3I). Thus, compared with those in WT and *Ikka*^{ASOE}*Stat3*^{ASOE} mice, oral neutrophils
 700 in *Ikka*^{ASOE} mice exhibited increased *Il1b* expression but reduced ROS and phagocytosis gene signatures
 701 (Fig. 3J).

702 Because oral instillation exposes fungi directly to oral neutrophils, epithelial cells, and TME, we
 703 compared neutrophils from the buccal mucosa, blood, and skin across WT, *Ikka*^{ASOE}, and *Ikka*^{ASOE}*Stat3*^{ASOE}
 704 mice following *C. cladosporioides* infection (Fig. 3J). Skin neutrophils showed similar but less
 705 pronounced alterations compared with oral neutrophils, whereas blood neutrophils exhibited minimal
 706 changes (Fig. 3J; Supplementary Fig. S5C–S5E). In addition, the oral cavity of infected *Ikka*^{ASOE} mice
 707 showed an increased TAM signature score, including genes *Cd163*, *Csf1r*, *Trem2*, *Lgals3*, *Folr2*, *Gpnmb*,
 708 *Spp1*, *Cd14*, *Ctss*, and *Ccl6* (Fig. 3K; Supplementary Fig. S5E). Oral macrophage infiltration was also
 709 higher in *Ikka*^{ASOE} mice than in WT and *Ikka*^{ASOE}*Stat3*^{ASOE} mice (Supplementary Fig. S4I). *Il1b* expression
 710 in oral macrophages was also higher in *Ikka*^{ASOE} mice than in *Ikka*^{ASOE}*Stat3*^{ASOE} mice, although it did not
 711 differ significantly between WT and *Ikka*^{ASOE} mice (Supplementary Fig. S5F). Collectively, these results
 712 suggest that oral neutrophils and macrophages contribute to the elevated serum IL-1 β levels observed in
 713 fungus-infected *Ikka*^{ASOE} mice.

714
 715 ***C. cladosporioides* induces STAT3-dependent secretion of acidic metabolites by epithelial tumor**
 716 **cells and in the oral cavity of *Ikka*^{ASOE} mice**

717 The increased oral fungal colonization in *Ikka*^{ASOE} mice requires epithelial cell STAT3 activity,
 718 suggesting involvement of downstream STAT3 targets. STAT3 regulates expression of HIF-1 α (42) and
 719 of HK2, a target of HIF-1 α required for glycolysis (43). Infection can elevate glucose metabolism (44,45),
 720 leading to the production of glycolytic metabolites such as lactate that promote tumor progression (46).
 721 We analyzed by RNA-seq the transcriptome of human SCC A431 cells exposed or not to *C.*
 722 *cladosporioides*. Fungal exposure upregulated genes involved in glucose transmembrane transport,
 723 including *TRIB3*, *CAPN10*, *IRS1*, *FGF19*, and *IL1B*, as well as HIF-1 α targets related to glycolysis, such
 724 as *HK2*, *ENO2*, *JUN*, *EP300*, and *CREB1* (Fig. 4A, left and right) (47,48). *C. cladosporioides* treatment

725 increased lactate levels in the supernatant of A431 cell cultures compared to untreated controls (Fig. 4B).
 726 Silencing *HIF1A* reduced *C. cladosporioides*–induced lactate levels (Supplementary Fig. S6A). In vitro,
 727 fungal cell viability was not required for induction of glycolysis because exposure to heat-killed *C.*
 728 *cladosporioides* elevated the levels of glucose, lactate, and six intermediate metabolites in A431 and
 729 SCC25 cells in a STAT3-dependent manner (Fig. 4C–E; Supplementary Fig. S6B). Treatment with
 730 calphostin-C, a *C. cladosporioides* metabolite, also increased glucose and lactate levels in A431 cells
 731 (Supplementary Fig. S6C).

732 *C. cladosporioides* inoculation induced lactate production in the oral cavity of *Ikka*^{ASOE} mice but not
 733 in WT or *Ikka*^{ASOE}*Stat3*^{ASOE} mice. Notably, lactate production was observed only in *Ikka*^{ASOE} mice
 734 inoculated with *C. cladosporioides*, and not with *S. cerevisiae* (Fig. 4F). Lactate and lactic acid (LA) are
 735 inter-exchangeable forms of the same metabolite (49-51). Consistent with this, *C. cladosporioides*, not *S.*
 736 *cerevisiae*, reduced oral pH in *Ikka*^{ASOE} mice, but not in WT and *Ikka*^{ASOE}*Stat3*^{ASOE} mice (Fig. 4G;
 737 Supplementary Fig. S6D). Thus, *C. cladosporioides* infection induces secretion of acidic metabolites (LA
 738 and UA) in the oral cavity of *Ikka*^{ASOE} mice via a STAT3-dependent pathway.

739 *STAT3* expression positively correlated with *HIF1A* expression in 523 human HNSCC samples, and
 740 both genes also correlated with *HK2*, *JUN*, *EP300*, and *CREB1* expression (Fig. 4H). In addition, *HIF1A*,
 741 *TRIB3*, and *IL1B* expression was higher in 519 human HNSCCs than in 44 healthy controls
 742 (Supplementary Fig. S6E). HNSCC patients whose tumors expressed high levels of both *STAT3* and
 743 *HIF1A* had poorer survival than those with lower expression of these genes (Supplementary Fig. S6F).
 744 HIF-1 α IHC staining was stronger in human HNSCC sections than in healthy human oral epithelium and
 745 was also increased in oral lesions of *C. cladosporioides*–inoculated *Ikka*^{ASOE} mice compared to fungus-
 746 inoculated *Ikka*^{ASOE}*Stat3*^{ASOE} and WT mice (Supplementary Fig. S6G and S6H). Together, these findings

747 support a shared phenotype between HNSCC patients and the mouse model, characterized by enhanced
 748 glucose metabolic pathway that promotes lactate secretion.

749
 750 **Acidic metabolites inhibit *C. cladosporioides*–induced ROS production and fungitoxicity, but**
 751 **promote IL-1 β expression in neutrophils**

752 In response to oral *C. cladosporioides* infection, fungal colonization, increased infiltration of
 753 neutrophils with aberrant signatures, and elevated levels of UA and LA, were observed in *Ikka*^{ASOE} mice,
 754 but not in WT and *Ikka*^{ASOE}*Stat3*^{ASOE} mice. Therefore, we tested whether UA and LA influence neutrophil
 755 activity following fungal stimulation. *C. cladosporioides* treatment increased ROS and IL-1 β production
 756 in neutrophils isolated from the bone marrow (BM) and blood of WT mice (Fig. 5A; Supplementary Fig.
 757 S7A). Consistently, fungal treatment of BM neutrophils elevated NOX2 levels, whereas LA repressed
 758 fungus-induced NOX2 expression (Supplementary Fig. S7B). Treatment of neutrophils with LA or UA
 759 suppressed fungus-induced ROS production but enhanced IL-1 β expression (Fig. 5A), indicating that
 760 while *C. cladosporioides* induces ROS, LA or UA attenuates this response while promoting IL-1 β
 761 expression.

762 To elucidate the pathways through which *C. cladosporioides*, UA, and LA regulate neutrophil activity,
 763 we treated BM neutrophils with the fungus and acidic metabolites. RNA-seq analysis revealed that *C.*
 764 *cladosporioides*, but not LA or UA, stimulated ROS-producing pathways and *Il1b* expression (Fig. 5B;
 765 Supplementary Fig. S7C). However, treatment of neutrophils with UA or LA inhibited fungus-induced
 766 expression of genes involved in ROS production and phagocytosis, while modestly enhancing the
 767 expression of *Il1b*, *Nlrp3*, and related inflammatory pathways, as shown by GO pathway and heatmap
 768 analyses (Fig. 5C–F). We confirmed that LA or UA suppressed fungus-induced expression of genes
 769 encoding two key receptors involved in phagocytosis: CD302, a C-type lectin receptor, and TLR2 (Fig.

5D, right) (52,53). Neutrophils kill pathogens in part through the formation of neutrophil extracellular traps (NETs) (54). To examine the effect of these metabolites on NETs formation, BM neutrophils were treated with live *C. cladosporioides* alone or in combination with UA or LA. Both UA or LA significantly inhibited *C. cladosporioides*-induced NETs formation (Fig. 5G and H, left; Supplementary Fig. S7D). To assess neutrophil-mediated fungitoxicity, an equal volume of each culture supernatant was added to YPD medium. Supernatants from neutrophils treated with *C. cladosporioides* alone markedly inhibited fungal growth, whereas this fungicidal effect was absent in supernatants from co-cultures treated with *C. cladosporioides* and either LA or UA (Fig. 5H, left, middle, and right). These results suggest that the metabolites suppress the fungicidal activity of neutrophils, mimicking the oral microenvironment observed in *C. cladosporioides*-infected *Ikka*^{ASOE} mice (Fig. 5I).

780

781 **IL-1 β and *C. cladosporioides* activate STAT3 in SCC cells**

As increased fungal colonization was associated with enhanced oral tumor progression in *C. cladosporioides*-infected *Ikka*^{ASOE} mice, we investigated whether *C. cladosporioides* induces the expression of oncogenic molecules in tumor cells using RNA-seq analysis. Many genes with pro-tumorigenic activity were among the top 20 upregulated genes by the fungus (Supplementary Fig. S8A, left). Gene set enrichment and volcano plot analyses showed that fungal stimulation significantly activated multiple pathways, including IL-1 β /STAT3/cyclin D1 and STAT3/HIF-1 α /HK2 signaling (Fig. 6A and B; Supplementary Fig. S8A, right).

Because *C. cladosporioides* infection in *Ikka*^{ASOE} mice results in epithelial STAT3-dependent oral fungal expansion and in an increase of IL-1 β in oral neutrophils and of IL-1 β and IL-17A in the serum, we next investigated how these cytokines and *C. cladosporioides* influence STAT3 activity on tumor cells. Treatment with IL-1 β , IL-17A, and heat-killed or live *C. cladosporioides* strains isolated from either mice

793 or humans induced p-STAT3, cyclin D1, and HIF-1 α in human SCC cell lines A431 and SCC25, although
 794 with varying efficiency (Fig. 6C and D; Supplementary Fig. S8B–S8E, left). In contrast, heat-killed *S.*
 795 *cerevisiae* or *Ramularia spp.* isolated from human sputum failed to elicit these effects in A431 cells (Fig.
 796 6D; Supplementary Fig. S8E, right). RT-PCR confirmed that *C. cladosporioides* induced *STAT3*
 797 expression and stimulated STAT3-dependent *IL1B* and *CCND1* expression in A431 and SCC25 cells (Fig.
 798 6E; Supplementary Fig. S8F).

799 Fungus-induced endocytosis has been reported to activate EGFR on epithelial cells (55). Calphostin-
 800 C, a metabolite produced by *C. cladosporioides* that activates EGFR (19,56), was also found to stimulate
 801 STAT3 activity and induce cyclin D1 expression (Fig. 6F). STAT3 can be a downstream target of EGFR
 802 signaling (20,57). Previously, we showed that the EGFR inhibitor GW2974 diminishes skin SCC
 803 development driven by *Ikka* ablation in keratinocytes (21). To determine whether EGFR is required for
 804 calphostin-C- or *C. cladosporioides*-induced STAT3 activation, we treated A431 and SCC25 cells with
 805 the EGFR inhibitors GW2974 and AZD9291 (58), respectively, for 3 hours before exposure to *C.*
 806 *cladosporioides*. These inhibitors effectively blocked *C. cladosporioides*-induced p-EGFR and p-STAT3
 807 levels (Fig. 6F; Supplementary Fig. S8G and S8H). Consistently, GW2974 also blocked calphostin-C-
 808 induced EGFR and STAT3 activation in A431 cells (Fig. 6F; Supplementary Fig. S8I). Increased p-EGFR
 809 staining was observed in oral cells of *C. cladosporioides*-infected *Ikka*^{ASOE} mice compared to WT mice
 810 (Supplementary Fig. S4C). Moreover, oral administration of GW2974 significantly reduced fungal
 811 colonization in the oral cavity of oral *C. cladosporioides*-infected *Ikka*^{ASOE} mice relative to vehicle
 812 controls (Fig. 6G), demonstrating that EGFR inhibition recapitulates the effect of *Stat3* depletion *in vivo*
 813 and *in vitro* on fungal growth.

814 In addition, both *C. cladosporioides* and calphostin-C promoted cell cycle progression (Supplementary
 815 Fig. S8J). However, the gene expression profile induced by *C. cladosporioides* was substantially broader

816 than that induced by calphostin-C, suggesting that calphostin-C contributes only partially to the activity
 817 of *C. cladosporioides*. Overall, these findings indicate that microenvironmental IL-1 β and IL-17A and *C.*
 818 *cladosporioides* can activate epithelial cell STAT3 signaling and its downstream targets (Fig. 6H).

819

820 **Oral *C. cladosporioides* infection enhances distal tumor growth by inducing systemic IL-1 β**

821 Oral *C. cladosporioides* inoculation also significantly enhanced *Ikka*-deletion-initiated, STAT3-
 822 dependent skin carcinogenesis (Fig. 7A; Supplementary Fig. S9A). The expression of p-STAT3, cyclin
 823 D1, and p-EGFR, as well as STAT3-dependent proliferation, were increased in K5⁺ keratinocytes of skin
 824 tumors from *Ikka*^{ASOE} mice compared to normal skin from WT mice (Fig. 7B; Supplementary Fig. S9B
 825 and S9C). Compared to WT cells, K5- and K15-positive keratinocytes in *Ikka*^{ASOE} mice exhibited elevated
 826 expression of numerous genes that may contribute to skin carcinogenesis, as analyzed by scRNA-seq
 827 (Supplementary Fig. S9D, S9E, and S5A). These genes included markers associated with keratinocyte
 828 hyperproliferation, growth factor and MAPK pathway activation, stem cell identity, host defense
 829 responses, inflammatory pathways, and glucose metabolism (Supplementary Fig. S9E).

830 Lung tumors in *Ikka*-deficient mice present an immunosuppressive TME with increased ROS⁺
 831 macrophages and Foxp3⁺ regulatory T (Treg) cells (20,21,59). Similarly, IHC staining revealed increased
 832 numbers of p-STAT3⁺ epidermal keratinocytes, macrophages, and Treg cells in the skin of *Ikka*^{ASOE} mice
 833 compared to WT and *Ikka*^{ASOE}*Stat3*^{ASOE} mice. Oral *C. cladosporioides* inoculation in *Ikka*^{ASOE} mice further
 834 enhanced these skin cell populations (Fig. 7C; Supplementary Fig. S9F). Notably, no increased fungal
 835 growth was observed in the skin of any of the six mouse groups, regardless of oral fungal inoculation
 836 (Supplementary Fig. S9G), and no increase in IL-17A⁺CD4⁺ T cells was detected in the skin of orally
 837 infected *Ikka*^{ASOE} mice. Thus, oral fungal infection may induce systemic mediators that contribute to distal
 838 tumorigenesis.

839 Because oral fungal infection significantly increased infiltrating macrophages in the skin of *Ikka*^{ΔSOE}
840 mice compared to uninfected *Ikka*^{ΔSOE} mice, we analyzed, using scRNA-seq, the skin macrophages
841 expressing *Csf1r*, *Lyz2*, and *Itgam*, as well as the skin neutrophils expressing *Csf3r* and *S100a8* (Fig. 7D).
842 In UMAP plots, the macrophage cluster was much larger than the neutrophil population, suggesting that
843 macrophages are the predominant immune population contributing to the pro-cancer TME. UMAP
844 analysis revealed that *Il1b* and *Nlrp3* expression in macrophages were highly similar (Fig. 7D). The
845 expression of *Il1b*, *Nlrp3*, *Cybb*, *Cyba*, *Cxcl16*, and *Ccl3* as well as TAM genes (*Csf1r*, *Trem2*, *Spp1*,
846 *Apoe*, *Lgals3*, *Pla2g7*, and *Tgfb1*), was markedly upregulated in skin macrophages from *Ikka*^{ΔSOE} mice
847 compared to those from WT mice (Fig. 7E; Supplementary Fig. S9H). Based on *Il1b* expression, skin
848 macrophages were classified into two subsets: *Cybb*⁺*Il1b*⁺ and *Cybb*⁺*Il1b*⁻ (Fig. 7F). *Cybb*⁺*Il1b*⁺
849 macrophages displayed an inflammatory phenotype characterized by high expression of genes encoding
850 inflammatory regulators (*Il1a*, *Tnf*, *Cd274*, *Tnfrsf1b*, *Cxcl2*, and *Ccl4*) and multiple cytokine and
851 chemokine receptors, along with reduced expression of genes encoding C-type lectin PRRs, such as
852 CD209f, CD209g, and CD209d (Fig. 7F) (60). *Cybb*⁺*Il1b*⁻ macrophages highly expressed genes encoding
853 complement components (61), C-type lectin PRRs (62), and regulators of phagocytosis, including *Cd163*,
854 *Mrc1*, *C4b*, *Cd209s*, and *Cd36* (Fig. 7F) (63-66). The proportion of inflammatory *Cybb*⁺*Il1b*⁺ macrophage
855 was increased in the skin of *Ikka*^{ΔSOE} mice compared to WT mice (Fig. 7G, left).

856 Additionally, skin macrophages from *Ikka*^{ΔSOE} mice exhibited increased expression of genes involved
857 in inflammatory responses, IL-1 cytokine production pathways, NADH regeneration, ROS metabolism,
858 and innate immune response, while showing decreased expression of *Cd209* and complement component
859 genes, along with reduced phagosome activity, C-type lectin receptor signaling, and cellular responses to
860 pathogens compared to WT mice (Fig. 7G, right). Furthermore, oral *C. cladosporioides* infection elevated
861 IL-1β and ROS levels in skin macrophages from infected *Ikka*^{ΔSOE} mice compared to uninfected *Ikka*^{ΔSOE}

862 mice (Fig. 7H). These findings suggest that the expansion of inflammatory IL-1 β -expressing
863 macrophages is associated with skin tumor progression induced by oral fungal infection.

864 IL-1 β , a key cytokine that promotes a pro-inflammatory TME, stimulates expression of its own gene
865 in both macrophages and neutrophils (67,68). Treatment of BM and blood neutrophils from WT mice with
866 *C. cladosporioides* stimulated IL-1 β expression and ROS production (Fig. 5A; Supplementary Fig. S7A).
867 We hypothesized that systemic IL-1 β levels induced by oral *C. cladosporioides* inoculation may
868 contribute to skin tumor progression. To test this, we established a skin tumor model to dissect the roles
869 of oral *C. cladosporioides*, IL-1 β , oral neutrophils, and skin macrophages. We selected B16F, a skin
870 melanoma cell line capable of forming tumors within a short timeframe. The B16F melanoma model was
871 also well suited for this study because it has previously been used to investigate fungal contributions to
872 tumorigenesis (10). Consistent with the relevance of this model, patients with skin cutaneous melanomas
873 expressing low levels of *CHUK* exhibited worse survival than those with high *CHUK* expression
874 (Supplementary Fig. S9I). In addition, IL-1 β treatment induced p-STAT3 and HIF1A expression in B16F1
875 melanoma cells (Fig. 7I), while *STAT3* and *IL1B* macrophage signatures were highly correlated in human
876 skin cutaneous melanomas (Fig. 7J). We therefore subcutaneously injected B16F1 cells into C57BL/6 WT
877 mice (Fig. 7K). As the intratumoral neutrophil population in these skin tumors was markedly smaller than
878 the macrophage population (Supplementary Fig. S9J, left), we focused on tumor-associated macrophages.
879 Because WT mice rapidly clear oral fungal infections, repeated oral inoculations were necessary to
880 maintain sustained interactions between fungi and neutrophils in the oral cavity. After tumors developed
881 by day 8 following injection, oral *C. cladosporioides* inoculation every two days significantly promoted
882 B16F1 tumor growth, which was associated with increased oral IL-1 β ⁺ neutrophils, elevated serum IL-1 β
883 levels, and a higher number of IL-1 β ⁺ macrophages within tumors compared to uninfected mice (Fig. 7L–
884 P; Supplementary Fig. S9J, right). Treatment of orally fungus-infected mice with an anti-IL-1 β antibody

markedly reduced tumor volume and weight, accompanied by decreased numbers of oral IL-1 β ⁺ neutrophils, tumor-associated IL-1 β ⁺ macrophages, and serum IL-1 β levels compared to IgG-treated controls (Fig. 7L–P; Supplementary Fig. S9J). To confirm the role of fungal infection, we administered the antifungal drug Amphotericin B concurrently with oral fungal inoculation. This treatment inhibited subcutaneous tumor growth compared to mice receiving fungal inoculation alone (Fig. 7Q). Additionally, depletion of macrophages in orally fungus-infected mice using clodronate liposomes markedly reduced tumor-associated macrophages and blocked oral fungus-enhanced tumor growth compared to liposomes controls (Fig. 7R; Supplementary Fig. S9K). To confirm the roles of IL-1 β and IL-1R in BM-derived cells, we generated chimeric mice transplanted with *Il1b*^{-/-} or *Il1r1*^{-/-} BM and injected B16F1 cells into these mice. These chimeras exhibited reduced oral-fungus-enhanced tumorigenesis, decreased numbers of intratumoral IL-1 β ⁺ macrophage, and suppressed serum IL-1 β levels compared to chimeric mice with WT BM (Supplementary Fig. S9L and S9M).

Collectively, this grafted tumor model shows that systemic IL-1 β induced by oral *C. cladosporioides* infection promotes distal skin tumor growth through the cooperative actions of oral neutrophils and skin macrophages (Fig. 7S). These findings indicate that oral *C. cladosporioides* infection reshapes epithelial innate immunity to promote both local and distal tumor growth.

901

902 DISCUSSION

Accumulating evidence from both human studies and experimental animal models supports the presence of fungi within the TME and their role in carcinogenesis. In this study, we demonstrate that persistent oral infection with *C. cladosporioides* compromises local and distal epithelial innate resistance to pathogens and enhances tumor growth in a somatic mutation-driven spontaneous SCC mouse model. This model recapitulates key features of human HNSCC, including aberrant innate immune responses,

908 fungal colonization, activation of IL-1 β , STAT3, and EGFR signaling, and IKK α loss-induced oncogenic
 909 pathway. We show that fungal infection-induced acidic metabolites derived from tumor cells impair
 910 neutrophil phagocytotic activity, facilitating fungal persistence and colonization. In turn, the fungi and
 911 fungus-induced cytokines released by immune and epithelial cells stimulate tumor cell growth. These
 912 findings establish a mechanistic framework linking fungal activity to the development of an
 913 immunosuppressive TME.

914 The TME associated with HNSCC progression in both humans and mice is characterized by increased
 915 fungal burden, elevated infiltration of inflammatory *IL1B*-expressing neutrophils with impaired gene
 916 signature of ROS production and phagocytic activity, and accumulation of TAMs. *C. cladosporioides*, a
 917 fungal species detected in most in human HNSCCs, enhances *Ikka* deletion-induced oral SCC
 918 development in mice and increases oral fungal colonization through an EGFR-STAT3 pathway that
 919 promotes both tumor growth and fungal expansion. In vivo and in vitro studies demonstrate that *C.*
 920 *cladosporioides* stimulates epithelial-cell STAT3/Cyclin D1 signaling to promote cell cycle progression,
 921 and STAT3/HIF-1 α /glycolysis signaling that leads to the production of the acidic metabolite lactate (LA).
 922 In addition, oral *cladosporioides* infection in *Ikka*^{ASOE} mice induces, in a STAT3-dependent manner, the
 923 release of uric acid (UA), which increases NLRP3 expression (40) at oral malignant lesions. Together, the
 924 acidic metabolites LA and UA impair the phagocytic and fungicidal activities of neutrophils induced by
 925 *C. cladosporioides*, shifting them from protective, phagocytic neutrophils into inflammatory IL-1 β -
 926 expressing neutrophils and thereby worsening oral inflammation. These dysfunctional neutrophils fail to
 927 provide effective immune surveillance, allowing fungal expansion and establishing a synergistic loop
 928 among fungi, tumor cells, neutrophils, and TAMs that further amplifies oncogenic signaling.

929 Notably, oral fungal burden recruited neutrophils and macrophages. *C. cladosporioides* stimulated
 930 *Il1b* expression in neutrophils and treatment with an anti-IL-1 β antibody reduces the fungus-infection-

enhanced accumulation of both IL-1 β ⁺ neutrophils in the oral cavity and IL-1 β ⁺ TAMs in cutaneous tumors. These findings are consistent with the observation in human HNSCC, where increased *IL1B* expression in both neutrophils and TAMs is associated with advanced tumors. In line with our mouse studies, IL-1 β has been reported to upregulate its own expression in human neutrophils and macrophages via an IL-1 β /IL-1R-dependent positive feedback loop (67,68). Together, these findings suggest that elevated IL-1 β in the TME promotes macrophage recruitment and *IL1B* expression. *IL1B*-high neutrophils in advanced HNSCC exhibit reduced phagocytic capacity and diminished ROS signatures. Furthermore, recruited TAMs show increased expression of genes such as *SPPI1*, *GPNMB*, *TREM2*, *FOLR2*, *APOE*, *VSIG4*, and *CD14*, which promote cell growth, angiogenesis, and metastasis, as well as phagocytic activity that clears debris within the TME (69). Whether macrophages compensate for impaired neutrophil function remains to be determined. The interactions between neutrophils and macrophages in infection-associated carcinogenesis warrant further investigation.

Moreover, our data show that the extent of reduction in tumor-associated IL-1 β ⁺ macrophages correlates with the degree of tumor growth inhibition when clodronate-liposomes treatment is compared with anti-IL-1 β antibody treatment. Recent studies have shown that targeting specific TAM populations can suppress tumorigenesis (37,69). Given the nonspecific nature of clodronate-liposomes treatment and its potential adverse effects, targeting IL-1 β ⁺ macrophages may represent a more precise therapeutic strategy for cancer.

Although oral *C. cladosporioides* infection does not lead to fungal dissemination to the skin in mice, elevated serum IL-1 β levels were identified as a potential promoter of skin tumorigenesis. The skin TME associated with enhanced skin carcinogenesis exhibited increased levels of IL-1 β , NLRP3, ROS, IL-1 β ⁺ TAMs, and inflammation activators. While WT mice rapidly clear oral fungi, *C. cladosporioides* still induces IL-1 β expression in WT neutrophils. Using a fast-growing skin tumor mouse model, we

954 demonstrate that repeated oral inoculation with *C. cladosporioides* promotes skin tumor growth through
955 a systemic IL-1 β axis involving oral neutrophils, circulating IL-1 β , and TAMs. Blockade of IL-1 β in any
956 of these IL-1 β ⁺ compartments is sufficient to suppress tumor progression, establishing IL-1 β as a central
957 systemic driver linking oral fungal exposure to distal tumor growth.

958 Studies have identified inborn errors in *CHUK* in patients with autoimmune diseases, which are
959 associated with increased susceptibility to fungal infections (70-72). Patients with autoimmune diseases
960 caused by mutations in the autoimmune regulator gene (*AIRE*) or in genes that regulate *AIRE* expression,
961 as well as those with gain-of-function mutations in *STAT1*, are highly susceptible to fungal infections and
962 exhibit an increased risk of developing oral and esophageal SCC, as well as gastrointestinal carcinomas
963 (9,71,73,74), suggesting that increased susceptibility to fungal infection is closely associated with SCC
964 pathogenesis. Here, we show that *Ikka* deletion-mediated SCC and fungus-enhanced SCC progression
965 converge on the EGFR and STAT3 pathways, and that increased *IL1B* expression depends on STAT3 in
966 human SCC cells and in the TME of animal models. Consistent with these findings, patients with HNSCC
967 who exhibited similar molecular patterns have poorer survival.

968 Further studies are needed to determine whether increased fungal infection alters the compositions of
969 oral and gut microbiota, thereby affecting the TME and carcinogenesis. In this study, the scRNA-seq
970 analysis was restricted to neutrophils and TAMs, and future studies will explore broader immune and
971 epithelial remodeling driven by local fungal interactions and systemic inflammation.

972

973 **Authors' contributions**

974 N-Y.S., J.W., F.Z., and Y.H. initiated the project. X.L., A.K.S., J.H.B., and R.D.N. further revealed
975 the mechanism. X.L., N-Y.S., A.K.S., J.W.B., D.T., F.Z., G.S., S.B., and T.G. performed various animal,
976 biological, molecular, and histological analyses. X.L., J.H.B., R.D.N., C.J., C.O., K.C., X.X., T.A., Y.Z.,

977 Z.S., B.T., and X.W. performed RNA sequencing, single-cell RNA sequencing and mass spectrometry as
978 well as analysis. M.S.L., E.M.N.F., S.S., and P.Z. provided human samples and histology examination.
979 Y.H. and G.T. provided conceptualization and wrote the manuscript.

980

981 **Acknowledgments**

982 This research was supported by the Intramural Research Program of the National Institutes of Health
983 (NIH): Center for Cancer Research, National Cancer Institute (ZIA BC011212 and ZIA BC011391 to
984 Y.H.; ZIA BC 010793, ZIA BC 011152 and ZIA BC 011153 to G.T.); by the National Institute of Allergy
985 and Infectious Diseases (ZIA AI001175-1 to M.S.L.); by the National Research Foundation of Korea (RS-
986 2026-25475913 to N.-Y.S.); and by the National Cancer Institute under Contract No. 75N91025F00016
987 (Z.S., K.C., X.X., T.G., T.A., Y.Z., B.T., X.W.). The contributions of the NIH authors were made as part
988 of their official duties as NIH federal employees, are in compliance with agency policy requirements, and
989 are considered Works of the United States Government. However, the findings and conclusions presented
990 in this paper are those of the authors and do not necessarily reflect the views of the NIH or the U.S.
991 Department of Health and Human Services.

992

993 **The authors declare no use of AI-assisted technologies and writing processes.**

994

995 **Competing interests**

996 The authors declare no competing interests.

997

998 **Note**

999 Supplemental data for this article are available at Cancer Research Online.

1000

1001 **References**

1002

- 1003 1. Li D, Wu M. Pattern recognition receptors in health and diseases. *Signal Transduct Target Ther*
1004 2021;6:291.
- 1005 2. Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and
1006 plasticity in tumour progression and therapy. *Nat Rev Cancer* 2020;20:485–503.
- 1007 3. Masucci MT, Minopoli M, Carriero MV. Tumor Associated Neutrophils. Their Role in
1008 Tumorigenesis, Metastasis, Prognosis and Therapy. *Front Oncol* 2019;9:1146.
- 1009 4. Desai JV, Lionakis MS. The role of neutrophils in host defense against invasive fungal infections.
1010 *Curr Clin Microbiol Rep* 2018;5:181–9.
- 1011 5. Zhu F, Hu Y. Integrity of IKK/NF-kappaB Shields Thymic Stroma That Suppresses Susceptibility
1012 to Autoimmunity, Fungal Infection, and Carcinogenesis. *Bioessays* 2018;40(4):e1700131.
- 1013 6. Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, Kim JI, *et al.* The fungal mycobiome promotes
1014 pancreatic oncogenesis via activation of MBL. *Nature* 2019;574:264–7.
- 1015 7. Narunsky-Haziza L, Sepich-Poore GD, Livyatan I, Asraf O, Martino C, Nejman D, *et al.* Pan-
1016 cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. *Cell*
1017 2022;185:3789–806 e17.
- 1018 8. Yew SM, Chan CL, Ngeow YF, Toh YF, Na SL, Lee KW, *et al.* Insight into different
1019 environmental niches adaptation and allergenicity from the *Cladosporium sphaerospermum*
1020 genome, a common human allergy-eliciting *Dothideomycetes*. *Sci Rep* 2016;6:27008.
- 1021 9. Zhu F, Willette-Brown J, Song NY, Lomada D, Song Y, Xue L, *et al.* Autoreactive T Cells and
1022 Chronic Fungal Infection Drive Esophageal Carcinogenesis. *Cell Host Microbe* 2017;21:478–93
1023 e7.
- 1024 10. Shiao SL, Kershaw KM, Limon JJ, You S, Yoon J, Ko EY, *et al.* Commensal bacteria and fungi
1025 differentially regulate tumor responses to radiation therapy. *Cancer Cell* 2021;39:1202–13 e6.
- 1026 11. Rahal Z, Kadara H. Beyond bacteria: How the intratumor mycobiome modulates lung
1027 adenocarcinoma progression. *Cancer Cell* 2023;41:1846–8.
- 1028 12. Alam A, Levanduski E, Denz P, Villavicencio HS, Bhatta M, Alhorebi L, *et al.* Fungal mycobiome
1029 drives IL-33 secretion and type 2 immunity in pancreatic cancer. *Cancer Cell* 2022;40:153–67 e11.
- 1030 13. Liu NN, Yi CX, Wei LQ, Zhou JA, Jiang T, Hu CC, *et al.* The intratumor mycobiome promotes
1031 lung cancer progression via myeloid-derived suppressor cells. *Cancer Cell* 2023 doi
1032 10.1016/j.ccell.2023.08.012.
- 1033 14. Underhill DM, Iliev ID. The mycobiota: interactions between commensal fungi and the host
1034 immune system. *Nat Rev Immunol* 2014;14:405–16.
- 1035 15. Grotz KA, Genitsariotis S, Vehling D, Al-Nawas B. Long-term oral *Candida* colonization,
1036 mucositis and salivary function after head and neck radiotherapy. *Support Care Cancer*
1037 2003;11:717–21.
- 1038 16. Bagg J, Sweeney MP, Lewis MA, Jackson MS, Coleman D, Al MA, *et al.* High prevalence of non-
1039 albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced
1040 cancer. *Palliat Med* 2003;17(6):477–81 doi 10.1191/0269216303pm793oa.
- 1041 17. Perera M, Al-Hebshi NN, Perera I, Ipe D, Ulett GC, Speicher DJ, *et al.* A dysbiotic mycobiome
1042 dominated by *Candida albicans* is identified within oral squamous-cell carcinomas. *J Oral*
1043 *Microbiol* 2017;9:1385369.

- 1044 18. Shay E, Sangwan N, Padmanabhan R, Lundy S, Burkey B, Eng C. Bacteriome and mycobiome
1045 and bacteriome-mycobiome interactions in head and neck squamous cell carcinoma. *Oncotarget*
1046 2020;11:2375–86.
- 1047 19. Gamou S, Shimizu N. Calphostin-C stimulates epidermal growth factor receptor phosphorylation
1048 and internalization via light-dependent mechanism. *J Cell Physiol* 1994;158:151–9.
- 1049 20. Liu B, Willette-Brown J, Liu S, Chen X, Fischer SM, Hu Y. IKKalpha represses a network of
1050 inflammation and proliferation pathways and elevates c-Myc antagonists and differentiation in a
1051 dose-dependent manner in the skin. *Cell death and differentiation* 2011;18:1854–64.
- 1052 21. Liu B, Xia X, Zhu F, Park E, Carbajal S, Kiguchi K, *et al.* IKKalpha is required to maintain skin
1053 homeostasis and prevent skin cancer. *Cancer Cell* 2008;14:212–25.
- 1054 22. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk
1055 in cancer. *Cytokine Growth Factor Rev* 2010;21:11–9.
- 1056 23. Stark GR, Darnell JE, Jr. The JAK-STAT pathway at twenty. *Immunity* 2012;36:503–14.
- 1057 24. Zhu F, Willette-Brown J, Zhang J, Ferre EMN, Sun Z, Wu X, *et al.* NLRP3 Inhibition Ameliorates
1058 Severe Cutaneous Autoimmune Manifestations in a Mouse Model of Autoimmune
1059 Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy-Like Disease. *J Invest Dermatol* 2020 doi
1060 10.1016/j.jid.2020.10.016.
- 1061 25. Xia X, Liu S, Xiao Z, Zhu F, Song NY, Zhou M, *et al.* An IKKalpha-Nucleophosmin Axis Utilizes
1062 Inflammatory Signaling to Promote Genome Integrity. *Cell reports* 2013;5:1243–55.
- 1063 26. Jones KB, Furukawa S, Marangoni P, Ma H, Pinkard H, D'Urso R, *et al.* Quantitative Clonal
1064 Analysis and Single-Cell Transcriptomics Reveal Division Kinetics, Hierarchy, and Fate of Oral
1065 Epithelial Progenitor Cells. *Cell Stem Cell* 2019;24:183–92 e8.
- 1066 27. Joost S, Annusver K, Jacob T, Sun X, Dalessandri T, Sivan U, *et al.* The Molecular Anatomy of
1067 Mouse Skin during Hair Growth and Rest. *Cell Stem Cell* 2020;26:441–57 e7.
- 1068 28. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, 3rd, Zheng S, Butler A, *et al.* Integrated analysis
1069 of multimodal single-cell data. *Cell* 2021;184:3573–87 e29.
- 1070 29. Vincent D Blondel, Jean-Loup Guillaume RL, Lefebvre E. Fast unfolding of communities in large
1071 networks. *Journal of Statistical Mechanics: Theory and Experiment* 2008;P100008.
- 1072 30. McDavid A, Finak G, Chattopadhyay PK, Dominguez M, Lamoreaux L, Ma SS, *et al.* Data
1073 exploration, quality control and testing in single-cell qPCR-based gene expression experiments.
1074 *Bioinformatics* 2013;29:461–7.
- 1075 31. Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, *et al.* Reference-based analysis of lung single-
1076 cell sequencing reveals a transitional profibrotic macrophage. *Nat Immunol* 2019;20:163–72.
- 1077 32. Miao Z, Deng K, Wang X, Zhang X. DEsingle for detecting three types of differential expression
1078 in single-cell RNA-seq data. *Bioinformatics* 2018;34:3223–4.
- 1079 33. Xie X, Shi Q, Wu P, Zhang X, Kambara H, Su J, *et al.* Single-cell transcriptome profiling reveals
1080 neutrophil heterogeneity in homeostasis and infection. *Nat Immunol* 2020;21:1119–33.
- 1081 34. Swamydas M, Lionakis MS. Isolation, purification and labeling of mouse bone marrow neutrophils
1082 for functional studies and adoptive transfer experiments. *J Vis Exp* 2013:e50586 doi
1083 10.3791/50586.
- 1084 35. Cillo AR, Kurten CHL, Tabib T, Qi Z, Onkar S, Wang T, *et al.* Immune Landscape of Viral- and
1085 Carcinogen-Driven Head and Neck Cancer. *Immunity* 2020;52:183–99 e9.
- 1086 36. Williams DW, Greenwell-Wild T, Brenchley L, Dutzan N, Overmiller A, Sawaya AP, *et al.*
1087 Human oral mucosa cell atlas reveals a stromal-neutrophil axis regulating tissue immunity. *Cell*
1088 2021;184:4090–104 e15.

- 1089 37. Mateus-Tique J, Lakshmi A, Singh B, Iyer R, Sanchez-Paulete AR, Falcomata C, *et al.* Armored
1090 macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control
1091 metastatic cancer growth. *Cancer Cell* 2026;44:534–50 e11.
- 1092 38. Blanpain C, Horsley V, Fuchs E. Epithelial stem cells: turning over new leaves. *Cell*
1093 2007;128:445–58.
- 1094 39. Kim DJ, Angel JM, Sano S, DiGiovanni J. Constitutive activation and targeted disruption of signal
1095 transducer and activator of transcription 3 (Stat3) in mouse epidermis reveal its critical role in
1096 UVB-induced skin carcinogenesis. *Oncogene* 2009;28:950–60.
- 1097 40. Braga TT, Forni MF, Correa-Costa M, Ramos RN, Barbuto JA, Branco P, *et al.* Soluble Uric Acid
1098 Activates the NLRP3 Inflammasome. *Sci Rep* 2017;7:39884 doi 10.1038/srep39884.
- 1099 41. Levy Y, Wiedemann A, Hejblum BP, Durand M, Lefebvre C, Surenaud M, *et al.* CD177, a specific
1100 marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.
1101 *iScience* 2021;24:102711 doi 10.1016/j.isci.2021.102711.
- 1102 42. Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M, *et al.* Signal transducer and activator of
1103 transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells
1104 and tumor-associated myeloid cells. *Mol Cancer Res* 2008;6:1099–105.
- 1105 43. Chen R, Li J, Zhou X, Liu J, Huang G. Fructose-1,6-Bisphosphatase 1 Reduces (18)F FDG Uptake
1106 in Hepatocellular Carcinoma. *Radiology* 2017;284:844–53.
- 1107 44. Bochicchio GV, Bochicchio KM, Joshi M, Ilahi O, Scalea TM. Acute glucose elevation is highly
1108 predictive of infection and outcome in critically injured trauma patients. *Ann Surg* 2010;252:597–
1109 602.
- 1110 45. McGuinness OP. Defective glucose homeostasis during infection. *Annu Rev Nutr* 2005;25:9–35.
- 1111 46. Yu L, Chen X, Wang L, Chen S. The sweet trap in tumors: aerobic glycolysis and potential targets
1112 for therapy. *Oncotarget* 2016;7:38908–26.
- 1113 47. Valle-Mendiola A, Soto-Cruz I. Energy Metabolism in Cancer: The Roles of STAT3 and STAT5
1114 in the Regulation of Metabolism-Related Genes. *Cancers (Basel)* 2020;12 doi
1115 10.3390/cancers12010124.
- 1116 48. Nagao A, Kobayashi M, Koyasu S, Chow CCT, Harada H. HIF-1-Dependent Reprogramming of
1117 Glucose Metabolic Pathway of Cancer Cells and Its Therapeutic Significance. *Int J Mol Sci*
1118 2019;20 doi 10.3390/ijms20020238.
- 1119 49. Choi SY, Collins CC, Gout PW, Wang Y. Cancer-generated lactic acid: a regulatory,
1120 immunosuppressive metabolite? *J Pathol* 2013;230:350–5.
- 1121 50. de la Cruz-Lopez KG, Castro-Munoz LJ, Reyes-Hernandez DO, Garcia-Carranca A, Manzo-
1122 Merino J. Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches.
1123 *Front Oncol* 2019;9:1143.
- 1124 51. Rostamian H, Khakpoor-Koosheh M, Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, Tavassolifar
1125 MJ, *et al.* Restricting tumor lactic acid metabolism using dichloroacetate improves T cell
1126 functions. *BMC Cancer* 2022;22:39.
- 1127 52. Levitz SM. Interactions of Toll-like receptors with fungi. *Microbes Infect* 2004;6:1351–5.
- 1128 53. Peng J, Li J, Liang J, Li W, Yang Y, Yang Y, *et al.* A C-type lectin-like receptor CD302 in yellow
1129 drum (*Nibea albiflora*) functioning in antibacterial activity and innate immune signaling. *Int J Biol*
1130 *Macromol* 2023;247:125734.
- 1131 54. Poli V, Zanoni I. Neutrophil intrinsic and extrinsic regulation of NETosis in health and disease.
1132 *Trends Microbiol* 2022 doi 10.1016/j.tim.2022.10.002.

- 1133 55. Zhu W, Phan QT, Boontheung P, Solis NV, Loo JA, Filler SG. EGFR and HER2 receptor kinase
1134 signaling mediate epithelial cell invasion by *Candida albicans* during oropharyngeal infection.
1135 *Proc Natl Acad Sci U S A* 2012;109:14194–9.
- 1136 56. Kobayashi E, Nakano H, Morimoto M, Tamaoki T. Calphostin C (UCN-1028C), a novel microbial
1137 compound, is a highly potent and specific inhibitor of protein kinase C. *Biochem Biophys Res*
1138 *Commun* 1989;159:548–53.
- 1139 57. Levy DE, Darnell JE, Jr. Stats: transcriptional control and biological impact. *Nat Rev Mol Cell*
1140 *Biol* 2002;3:651–62.
- 1141 58. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, *et al.* AZD9291, an
1142 irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
1143 *Cancer Discov* 2014;4:1046–61.
- 1144 59. Song NY, Li X, Ma B, Willette-Brown J, Zhu F, Jiang C, *et al.* IKK α -deficient lung
1145 adenocarcinomas generate an immunosuppressive microenvironment by overproducing Treg-
1146 inducing cytokines. *Proc Natl Acad Sci U S A* 2022;119.
- 1147 60. Jiang S, Sun L. Tongue Sole CD209: A Pattern-Recognition Receptor that Binds a Broad Range
1148 of Microbes and Promotes Phagocytosis. *Int J Mol Sci* 2017;18 doi 10.3390/ijms18091848.
- 1149 61. Gavin C, Meinke S, Heldring N, Heck KA, Achour A, Iacobaeus E, *et al.* The Complement System
1150 Is Essential for the Phagocytosis of Mesenchymal Stromal Cells by Monocytes. *Front Immunol*
1151 2019;10:2249 doi 10.3389/fimmu.2019.02249.
- 1152 62. Mnich ME, van Dalen R, van Sorge NM. C-Type Lectin Receptors in Host Defense Against
1153 Bacterial Pathogens. *Front Cell Infect Microbiol* 2020;10:309 doi 10.3389/fcimb.2020.00309.
- 1154 63. Pennathur S, Pasichnyk K, Bahrami NM, Zeng L, Febbraio M, Yamaguchi I, *et al.* The
1155 macrophage phagocytic receptor CD36 promotes fibrogenic pathways on removal of apoptotic
1156 cells during chronic kidney injury. *Am J Pathol* 2015;185:2232–45.
- 1157 64. N AG, Quintana JA, Garcia-Silva S, Mazariegos M, Gonzalez de la Aleja A, Nicolas-Avila JA, *et*
1158 *al.* Phagocytosis imprints heterogeneity in tissue-resident macrophages. *J Exp Med*
1159 2017;214:1281–96.
- 1160 65. Kneidl J, Loffler B, Erat MC, Kalinka J, Peters G, Roth J, *et al.* Soluble CD163 promotes
1161 recognition, phagocytosis and killing of *Staphylococcus aureus* via binding of specific fibronectin
1162 peptides. *Cell Microbiol* 2012;14:914–36.
- 1163 66. Healy LM, Jang JH, Won SY, Lin YH, Touil H, Aljarallah S, *et al.* MerTK-mediated regulation
1164 of myelin phagocytosis by macrophages generated from patients with MS. *Neurol Neuroimmunol*
1165 *Neuroinflamm* 2017;4:e402.
- 1166 67. Toda Y, Tsukada J, Misago M, Kominato Y, Auron PE, Tanaka Y. Autocrine induction of the
1167 human pro-IL-1 β gene promoter by IL-1 β in monocytes. *J Immunol* 2002;168:1984–91.
- 1168 68. Sims JE, Smith DE. The IL-1 family: regulators of immunity. *Nat Rev Immunol* 2010;10:89–102.
- 1169 69. Sun X, Park MD, Merad M, Brown BD. Macrophages: Targets for next-generation cancer
1170 immunotherapy. *Cancer Cell* 2026;44:498–518.
- 1171 70. Cadieux-Dion M, Safina NP, Engleman K, Saunders C, Repnikova E, Raje N, *et al.* Novel
1172 heterozygous pathogenic variants in CHUK in a patient with AEC-like phenotype, immune
1173 deficiencies and 1q21.1 microdeletion syndrome: a case report. *BMC Med Genet* 2018;19:41.
- 1174 71. Bainter W, Lougaris V, Wallace JG, Badran Y, Hoyos-Bachiloglu R, Peters Z, *et al.* Combined
1175 immunodeficiency with autoimmunity caused by a homozygous missense mutation in inhibitor of
1176 nuclear factor κ B kinase alpha (IKK α) *Sci Immunol* 2021;6:eabf6723.

- 1177 72. Cildir G, Aba U, Pehlivan D, Tvorogov D, Warnock NI, Ipsir C, *et al.* Defective kinase activity of
 1178 IKK α leads to combined immunodeficiency and disruption of immune tolerance in humans.
 1179 Nat Commun 2024;15:9944.
- 1180 73. Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, *et al.*
 1181 Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical
 1182 phenotype. Blood 2016;127:3154–64.
- 1183 74. Rautemaa R, Hietanen J, Niissalo S, Pirinen S, Perheentupa J. Oral and oesophageal squamous
 1184 cell carcinoma--a complication or component of autoimmune polyendocrinopathy-candidiasis-
 1185 ectodermal dystrophy (APECED, APS-I). Oral oncology 2007;43:607–13.

1188 Figure legends

1189 **Figure 1.** Advanced human HNSCCs show increased fungal burden, *IL1B*^{High}*CYBB*^{Low} neutrophils, and
 1190 TAM.

1191 **A**, FISH with a pan-fungal probe showing fungal signals in human healthy controls (HC), tumor adjacent
 1192 tissues (Adj), and HNSCCs (left, right).

1193 **B**, FISH confocal images with fungal probe (green) and DAPI (blue) in healthy tissue (left) and HNSCC
 1194 with an enlarged image (middle) from right section. Scale bar=100 μ m.

1195 **C**, Sequencing analyses (left) of fungal genus in DNA from paraffin sections of 20 human HNSCCs with
 1196 fungal names (right).

1197 **D**, Immunofluorescent (IF) staining with anti-*Cladosporium* antibody (green) in healthy tissue and
 1198 HNSCC. DAPI, blue. Scale bar=25 μ m.

1199 **E–F**, scRNA-seq analysis of CD45⁺ cells from 5 human healthy donor tonsils (HD) and 26 HNSCCs with
 1200 t-distributed stochastic neighbor embedding (tSNE) (GSE139324). Cluster 5*, neutrophils and
 1201 macrophages (**E**). *SI00A8* and *IL1B* expression in CD45⁺ cells and violin plot showing *IL1B* expression
 1202 in neutrophils in HD and HNSCCs (**F**).

1203 **G**, Expression of indicated genes or signature scores in *IL1B*-high and *IL1B*-Low neutrophils (n=24 HD,
 1204 n=2279 HNSCC cells).

1205 **H**, Heatmap showing gene expression in *IL1B*-High and *IL1B*-Low neutrophils from HNSCC. Fold
 1206 change $\geq$ 2.

1207 **I**, GSEA analysis of tumor-associated macrophage (TAM) signature. Genes listed on right. NES,
 1208 Normalized Enrichment Score.

1209 **J**, Violin plots showing indicated gene expression or signature scores correlated with neutrophils from
 1210 stage I–IV HNSCCs (GSE139324).

K, Violin plot showing TAM signature scores (left) and *IL1B* expression (right) in macrophages correlated with stage 1-IV HNSCCs (see Figure 1I, GSE139324).

L, Co-staining of confocal spatial images with IF-MPO, RNAscope-IL1B, IF-*Cladosporium*, and DAPI in HNSCCs (see Figure S9B). Scale bar=15 μ m.

M, Left: Kaplan-Meier curve displaying survival of HNSCC patients from TCGA stratified by expression of *IL1B*-High and *IL1B*-Low neutrophil signature (*IL1B*, *NLRP3*, *CXCL8*, *AREG*, *CSF3R*, *SOD2*, *FCGR3B*, and *TIMPI1*), normalized by *CSF3R* with quartile. Right: Spearman's correlation of *STAT3* and neutrophil *IL1B* signature (*IL1B*, *CSF3R*, *SOD2*, *FCGR3B*) in 519 human HNSCCs (GEPID2).

Data represent mean $\pm$ SEM. * P <0.05; ** P <0.01; *** P <0.001; **** P <0.0001; ns, not significant; as determined by Wilcoxon test (**F**, **G**, **J**, **K**) and Student's t-test (**A**).

Figure 2. Chronic oral *C. cladosporioides* infection increases *STAT3*-dependent oral carcinogenesis, fungal expansion, IL-1 β ⁺ neutrophil numbers, and serum IL-1 β /IL-17A levels.

A–B, Scheme for oral-fungal-infection-associated carcinogenesis. **M**, month (**A**). Incidence of oral epithelial malignancy in mice with and without *C. cladosporioides* (*Cladosp*) inoculation. Mouse numbers shown on top of each column (**B**).

C, Hematoxylin and eosin (H&E) staining for WT oral epithelium and SCC in *Ikka*^{ΔSOE} mice at endpoints of experiments. Scale bar=50 μ m.

D, Immunohistochemical (IHC) staining for p-*STAT3* and cyclin D1 (brown) in oral epithelium of mice at endpoints of experiments. Scale bar=40 μ m.

E–F, Survival of HNSCC patients carrying *CHUK* hemizygous deletion/*CCND1* gain and amplification compared to patients with diploid *CHUK/CCND1* expression (**E**, cBioPortal, *Nature*, 2015); survival of HNSCC patients expressing high *EGFR* (left) or *STAT3* (right) levels compared to those expressing low levels of these genes (**F**, cBioPortal, TCGA, HNSCC).

G, Fungal colonies from mouth of nine-month-old mice with and without oral fungal inoculation.

H, Flow cytometry showing IL-1 β ⁺- and ROS⁺-neutrophil and IL-17A⁺ CD4⁺ T cell numbers from mouth of fungus-infected mice.

I, Serum IL-1 β and IL-17A levels in nine-month-old mice, analyzed by bead-based flow cytometry.

J, Oral uric acid levels in mice at endpoints with and without oral *Cladosp* inoculation, analyzed with IF staining.

1241 **K**, IF stained-NLRP3 in oral tissues of mice at endpoints. Epi, epidermis between two white dashes
1242 indicated by arrows; ns, nonspecific staining indicated by arrow. Scale bar=50 μ m.

1243 **L**, Correlation of *NLRP3* and *IL1B* expression in 523 human HNSCCs (cBioPortal, PanCancer Atlas).

1244 Data represent mean $\pm$ SEM. * P <0.05; ** P <0.01; *** P <0.001; **** P <0.0001; ns, not significant; as
1245 determined by Fisher's exact test (**B**), log-rank test (**E**, **F**), and Student's t-test (**G**, **H**, **I**, **K**).

1246

1247 **Figure 3.** Oral *C. cladosporioides* infection induces oral neutrophils with High-*Il1b* and Low-
1248 ROS/phagocytosis signatures.

1249 **A–C**, UMAP plot from scRNA-seq showing cell clusters in oral buccal tissues of three fungus-infected
1250 mice at nine months of age (**A**). Neutrophil markers in CD45⁺ cells (**B**) and neutrophil cluster with multi-
1251 markers (**C**). Macro, macrophages; Neutro, neutrophils.

1252 **D**, Heatmap representing five neutrophil clusters based on *Il1b* levels.

1253 **E**, Five neutrophil cluster distributions in UMAP format.

1254 **F**, Gene expression in *Il1b*^{LOW} and *Il1b*^{HIGH} neutrophils.

1255 **G**, Distributions of five neutrophil clusters in oral cavities of mice with oral fungal infection.

1256 **H**, Differentially expressed genes in pathways related to neutrophil activities in *Ikka*^{ASOE} versus WT mice.

1257 **I**, Violin plots showing expression of indicated genes in neutrophils. Dotted lines indicate median values.

1258 **J**, Violin plots of indicated signature scores and gene expression in neutrophil clusters. Middle lines
1259 indicate median values. * and #, gene expression in *Ikka*^{ASOE} mice and WT mice.

1260 **K**, GSEA analysis of TAM signature. Genes listed at bottom.

1261 Data represent mean $\pm$ SEM. * P <0.05; ** P <0.01; **** P <0.0001; ns, not significant; as determined by
1262 Student's t-test (**I**) and Wilcoxon test (**J**).

1263

1264 **Figure 4.** *C. cladosporioides* infection increases acidic metabolite levels in oral cavity of *Ikka*^{ASOE} mice.

1265 **A**, Heatmaps for HIF1A-associated glucose metabolism (left) and glucose transmembrane transport
1266 signaling (right) in A431 cells treated with or without heat-killed *Cladosp* for 5 hours, analyzed by RNA-
1267 seq.

1268 **B**, Lactate levels in culture supernatants of A431 cells treated with or without heat-killed *Cladosp*.

1269 **C–D**, RT-PCR for indicated gene expression in A431 (**C**) and SCC25 (**D**) cells treated with or without
1270 heat-killed *Cladosp* and *STAT3* siRNA (si-STAT3). si-Ctrl, control siRNA.

1271 **E**, Glucose, intermediated metabolites, and lactate levels in A431 (left) and SCC25 cells (right) following
 1272 heat-killed *Cladosp* or DMSO (control, Ctrl) stimulation for 24 hours (n=3/group).

1273 **F**, Lactate levels in oral cavities of mice with oral fungal infection for two months.

1274 **G**, pH values in oral swabs of infected mice.

1275 **H**, Correlation of *HIF1A* (left) or *STAT3* (right) expression with indicated gene expression in human
 1276 HNSCCs (TCGA and PanCancer Atlas, 523 samples).

1277 Data represent mean $\pm$ SEM. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$; ns, not significant; as
 1278 determined by Student's t-test (**B**, **C**, **D**, **E**, **F**, **G**), two-tailed t-test (**H**).

1279

1280 **Figure 5.** Acidic metabolites inhibit *C. cladosporioides*–induced fungitoxicity but enhance IL-1 β
 1281 expression in neutrophils.

1282 **A**, Flow cytometry showing ROS (left) and IL-1 β levels (middle), with representative images (right) in
 1283 blood neutrophils of WT mice treated with heat-killed *Cladosp* (10 μ L), lactic acid (lactate), or uric acid
 1284 overnight.

1285 **B**, Volcano plot of RNA-seq for *Cladosp*–treated bone marrow (BM) neutrophils versus control. Increased
 1286 gene expression on right.

1287 **C**, Gene Ontology (GO) pathways shown in BM neutrophil controls, treatment with heat-killed *Cladosp*
 1288 versus neutrophils treated with *Cladosp* and lactic acid (LA) or uric acid (UA) overnight, analyzed by
 1289 gene set enrichment analysis (GSEA).

1290 **D**, Left: Heatmaps for phagocytosis signaling in control BM neutrophils; *Cladosp* treatment; *Cladosp*
 1291 treatment plus UA or LA overnight. Right: CPM (counts per million) levels of *Tlr2* and *Cd302* in
 1292 neutrophils treated with *Cladosp* or *Cladosp* + LA or UA.

1293 **E–F**, Heatmap for IL-1 β (**E**) and ROS (**F**) pathway in BM neutrophils (Control), treated with heat-killed
 1294 *Cladosp*, and treated with *Cladosp* with UA or LA overnight.

1295 **G**, Images of SYTOX-Green-stained BM neutrophils for neutrophil extracellular traps (NETs) after
 1296 cultured with live fungi for 16 hours. Scale bar=8 μ m.

1297 **H**, Left: NETs in neutrophil culture with *Cladosp* plus UA or LA. Middle: survived fungi (CFU) after
 1298 culturing neutrophils and fungi plus UA or LA. Right: Images of cultures.

1299 **I**, A model showing UA and LA generation pathways in an epithelial STAT3-dependent manner (left) and
 1300 effects of *Cladosp*, LA, and UA on neutrophil fungitoxicity (right).

1301 Data represent mean $\pm$ SEM. * P <0.05; ** P <0.01; *** P <0.001; **** P <0.0001; ns, not significant; as
 1302 determined by Student's t-test (A, D-right, H).

1303
 1304 **Figure 6.** *C. cladosporioides*, calphostin-C, IL-1 β , and IL-17A increase STAT3 activity in SCC cells.
 1305 A, GSEA from RNA-seq showing pathways in *C. cladosporioides*-treated A431 cells versus control cells.
 1306 Bars, normalized enrichment scores.
 1307 B, Volcano plot of RNA-seq showing differential gene expression in *C. cladosporioides*-treated A431
 1308 cells versus controls.
 1309 C–D, Immunoblots showing p-STAT3, STAT3, and cyclin D1 levels in A431 and SCC25 cells treated
 1310 with IL-1 β (10 ng/mL) or IL-17A (10 ng/mL) (C), or with heat-killed *C. cladosporioides* and *S. cerevisiae*
 1311 (D). kDa, protein sizes; β -actin, protein loading controls; Ctrl, vehicle control; m, minute; hr, hour.
 1312 E, RT-PCR showing *STAT3*, *IL1B*, and *CCND1* expression in A431 cells treated with *STAT3* siRNA (si-
 1313 *STAT3*), si-control (Si-Ctrl), or heat-killed *Cladosp*.
 1314 F, Immunoblots showing indicated protein levels in A431 cells treated with fungi, calphostin-C (10 nM),
 1315 or GW2974 (10 μ M).
 1316 G, Fungal growth in YPD (left) and colony images (right) for oral swabs of oral fungus-infected *Ikka* ^{Δ SOE}
 1317 mice treated with GW2974 or vehicle control.
 1318 H, A model for *C. cladosporioides*- and IL-1 β -led pathways in epithelial tumor cells.
 1319 Data represent mean $\pm$ SEM. ** P <0.01; *** P <0.001; as determined by Student's t-test (E, G).

1320
 1321 **Figure 7.** IL-1 β induced by oral fungal infection promotes distal tumor growth.
 1322 A, Incidence of skin carcinomas in mice with and without oral *Cladosp* inoculation. Mouse numbers on
 1323 top of each column.
 1324 B, IHC stained p-STAT3 and cyclin D1 in skin and SCCs of mice at endpoints. Scale bar=50 μ m.
 1325 C, IHC-stained p-STAT3⁺-epithelial cells and macrophages in epidermis of nine-month-old mice with
 1326 and without oral fungal inoculation.
 1327 D, UMAP plots with markers for skin macrophages and neutrophils of oral fungus infected-mice. neutro,
 1328 neutrophil; macro, macrophage.
 1329 E, Violin plots from scRNA-seq showing *Ilb*, *Nlrp3*, and *Cybb* levels in skin macrophages. Middle lines
 1330 indicate median values in plots.

1331 **F**, Heatmap showing transcriptomics in *Cybb⁺Il1b⁺* and *Cybb⁺Il1b⁻* skin macrophages from oral fungus-
 1332 infected mice.

1333 **G**, Left: Distributions of *Cybb⁺Il1b⁺* and *Cybb⁺Il1b⁻* skin macrophages. Right: GO analyses of various
 1334 pathways in skin macrophages of *Ikka^{ASOE}* versus WT mice. Blue and red bars, downregulated and
 1335 upregulated pathways.

1336 **H**, ROS levels in skin macrophages and IL-1 β ⁺ macrophages (%) of oral fungus-infected and uninfected
 1337 *Ikka^{ASOE}* mice.

1338 **I**, Immunoblot showing indicated protein levels in B16F1 cells treated with IL-1 β (10 ng/mL). Ctrl,
 1339 vehicle control; m, minute; hr, hour; β -actin, protein loading controls.

1340 **J**, Spearman's correlation of *STAT3* and *IL1B* macrophage signature (*IL1B*, *CSF1R*, *CD68*) in 461 human
 1341 skin cutaneous melanomas (SKCM, GEPIA2).

1342 **K**, A scheme for effects of IL-1 β induced by oral fungi on skin tumor growth derived from subcutaneous
 1343 cell injection.

1344 **L–P**, Effects of oral *Cladosp*-infection on B16F1 cell-induced tumor growth (n=5/group, L), tumor weight
 1345 (g, gram, M), IL-1 β ⁺ oral neutrophils (N), intratumoral IL-1 β ⁺-macrophages (O), and serum IL-1 β levels
 1346 (P) in WT mice treated with anti-IL-1 β antibody (Ab) or IgG.

1347 **Q**, Effects of Amphotericin B on oral *Cladosp*-promoted skin tumor growth (n=5/group).

1348 **R**, Effects of macrophage depletion on oral *Cladosp*-promoted tumor growth (left, n=5/group). Ctrl,
 1349 control; Lips, liposomes as negative controls; Clodronate-Lips, clodronate-coated liposomes.

1350 **S**, A model for effects of oral *Cladosp* infection-induced systemic IL-1 β on skin tumor growth. BM, bone
 1351 marrow; +, add; -, deletion; AmpB, Amphotericin B; arrows, promotion; crosslines, inhibition.

1352 Data represent mean $\pm$ SEM. * P <0.05; ** P <0.01; *** P <0.001; **** P <0.0001; ns, not significant; as
 1353 determined by Fisher's exact test (**A**), Student's t-test (**C**, **E**, **H**, **M–P**), and Wilcoxon test (**G**, **L**, **Q**, **R**).
 1354

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7

